Benitec Biopharma (BNTCW) 20-F 29 Oct 18 2018 FY Annual report (foreign) Financial data

Document and Entity Information

Document and Entity Information	12 Months Ended
	Jun. 30, 2018shares
Document And Entity Information [Abstract]
Document Type	20-F
Amendment Flag	false
Document Period End Date	Jun. 30, 2018
Document Fiscal Year Focus	2,018
Document Fiscal Period Focus	FY
Trading Symbol	BNTC
Entity Registrant Name	BENITEC BIOPHARMA LTD/ADR
Entity Central Index Key	1,552,795
Current Fiscal Year End Date	--06-30
Entity Well-known Seasoned Issuer	No
Entity Current Reporting Status	Yes
Entity Filer Category	Non-accelerated Filer
Entity Common Stock, Shares Outstanding	257,029,426

Consolidated Statement of Profi

Consolidated Statement of Profit or Loss and Other Comprehensive Income - AUD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2016
Income Statement [Abstract]
Revenue	$ 620	$ 586	$ 464
Other income	4,087	10,507	3,590
Total Income	4,707	11,093	4,054
Expenses
Royalties and licence fees	(451)	(272)	(139)
Research and development	(6,890)	(6,925)	(13,287)
Employee benefits expense	(5,094)	(5,015)	(6,283)
Share-based expense	(434)	(386)	(1,746)
Travel related costs	(468)	(629)	(1,023)
Consultants costs	(783)	(976)	(1,020)
Occupancy costs	(587)	(550)	(500)
Depreciation	(194)	(217)	(290)
Corporate expenses	(1,360)	(1,540)	(1,139)
Foreign exchange realized loss	(39)	(98)	(414)
Foreign exchange unrealized loss	(5)	(168)
IPO costs			(1,191)
Change in market value of listed investment	(41)
Loss on disposal of fixed assets	(1)	(7)
Write-off of clinical trial prepayment			(1,800)
Total Expenses	(16,347)	(16,783)	(28,832)
Loss before income tax	(11,640)	(5,690)	(24,778)
Income tax	0	0	0
Loss after income tax for the period attributable to the owners of Benitec Biopharma Limited	(11,640)	(5,690)	(24,778)
Other comprehensive income
Foreign currency translation loss	(63)	34	(19)
Total comprehensive loss for the period attributable to the owners of Benitec Biopharma Limited	$ (11,703)	$ (5,656)	$ (24,797)
Basic loss for the twelve months, cents per share	$ (0.0553)	$ (0.0324)	$ (0.1741)
Diluted loss for the twelve months, cents per share	$ (0.0553)	$ (0.0324)	$ (0.1741)

Consolidated Statement of Finan

Consolidated Statement of Financial Position - AUD ($) $ in Thousands	Jun. 30, 2018	Jun. 30, 2017
Current Assets
Cash and cash equivalents	$ 16,085	$ 17,375
Other financial assets	130	100
Trade and other receivables	4,255	4,406
Other assets	425	281
Total Current Assets	20,895	22,162
Non-Current Assets
Deposits	125	59
Plant and equipment	319	445
Total Non-Current Assets	444	504
TOTAL ASSETS	21,339	22,666
Current Liabilities
Trade and other payables	2,376	919
Provisions	171	206
Total Current Liabilities	2,547	1,125
Non-Current Liabilities
Provisions	48	35
Total Non-Current Liabilities	48	35
TOTAL LIABILITIES	2,595	1,160
NET ASSETS	18,744	21,506
EQUITY
Issued capital	164,087	155,580
Reserves	1,492	1,674
Accumulated losses	(146,835)	(135,748)
TOTAL EQUITY	$ 18,744	$ 21,506

Consolidated Statement of Chang

Consolidated Statement of Changes in Equity - AUD ($) $ in Thousands	Total	Issued Capital [Member]	Reserves [Member]	Accumulated Losses [Member]
Beginning balance at Jun. 30, 2015	$ 23,878	$ 129,631	$ 2,038	$ (107,791)
Loss after income tax benefit for the year	(24,778)			(24,778)
Other comprehensive income - Foreign exchange translation reserve	(19)		(19)
Total comprehensive loss for the period attributable to the owners of Benitec Biopharma Limited	(24,797)		(19)	(24,778)
Contributions of equity, net of transaction costs	18,010	18,010
Share-based payments	1,746		1,746
Transfer of expired share-based payments			(1,200)	1,200
Ending balance at Jun. 30, 2016	18,837	147,641	2,565	(131,369)
Loss after income tax benefit for the year	(5,690)			(5,690)
Other comprehensive income - Foreign exchange translation reserve	34		34
Total comprehensive loss for the period attributable to the owners of Benitec Biopharma Limited	(5,656)		34	(5,690)
Contributions of equity, net of transaction costs	7,939	7,939
Share-based payments	386		386
Transfer of expired share-based payments			(1,311)	1,311
Ending balance at Jun. 30, 2017	21,506	155,580	1,674	(135,748)
Loss after income tax benefit for the year	(11,640)			(11,640)
Other comprehensive income - Foreign exchange translation reserve	(63)		(63)
Total comprehensive loss for the period attributable to the owners of Benitec Biopharma Limited	(11,703)		(63)	(11,640)
Contributions of equity, net of transaction costs	8,507	8,507
Share-based payments	434		434
Transfer of expired share-based payments			(553)	553
Ending balance at Jun. 30, 2018	$ 18,744	$ 164,087	$ 1,492	$ (146,835)

Consolidated Statement of Cash

Consolidated Statement of Cash Flows - AUD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2016
Cash flows from operating activities
Receipts from customers	$ 237	$ 333	$ 340
Interest received	246	242	217
Government grants	4,112	6,274	3,590
Receipts of CRO prepayment	109	791
Payments to suppliers and employees	(14,498)	(15,944)	(24,355)
Net cash used in operating activities	(9,794)	(8,304)	(20,208)
Cash flows from investing activities
Payments for plant and equipment	(83)	(171)	(342)
Proceeds from disposal of plant and equipment	2
Security deposits		(131)
Clinical trial deposit	(66)
Net cash used in investing activities	(147)	(302)	(342)
Cash flows from financing activities
Proceeds from issue of shares	8,820	8,072	19,462
IPO and share issue transaction cost	(313)	(133)	(1,952)
Net cash from financing activities	8,507	7,939	17,510
Net (decrease)/increase in cash and cash equivalents	(1,434)	(667)	(3,040)
Cash and cash equivalents at beginning of the period	17,375	18,230	21,787
Effects of exchange rate changes on cash and cash equivalents	144	(188)	(517)
Cash and cash equivalents at end of the period	$ 16,085	$ 17,375	$ 18,230

Significant Accounting Policies

Significant Accounting Policies	12 Months Ended
	Jun. 30, 2018
Disclosure Of Significant Accounting Policies [Abstract]
Significant Accounting Policies	1. SIGNIFICANT ACCOUNTING POLICIES The principal accounting policies adopted in the preparation of the financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated. (a) Basis of preparation These general purpose financial statements have been prepared in accordance with Australian Accounting Standards and Interpretations issued by the Australian Accounting Standards Board ('AASB') and the Corporations Act 2001, as appropriate for for-profit oriented entities. These financial statements also comply with International Financial Reporting Standards as issued by the International Accounting Standards Board ('IASB'). Historical cost convention The financial statements have been prepared under the historical cost convention. Critical accounting estimates The preparation of the financial statements requires the use of certain critical accounting estimates. It also requires management to exercise its judgement in the process of applying the Group's accounting policies. The areas involving a higher degree of judgement or complexity, or areas where assumptions and estimates are significant to the financial statements, are disclosed in note 2. (b) New, revised or amending Accounting Standards and Interpretations adopted In the current year the Group has adopted all of the new, revised or amended Accounting Standards and interpretations issued by the Australian Accounting Standards Board (AASB) that were mandatory for current financial year. (c) New Accounting Standards and Interpretations not yet mandatory or early adopted Certain new accounting standards and interpretations have been published that are not mandatory for June 30, 2018 reporting periods and have not been early adopted by the group. The group’s assessment of the impact of these new standards and interpretations is set out below. • IFRS 9 Financial Instruments - addresses the classification, measurement and derecognition of financial assets and financial liabilities and introduces new rules for hedge accounting. In December 2014, the IASB made further changes to the classification and measurement rules and also introduced a new impairment model. These latest amendments now complete the new financial instruments standard. Impact - Based on the entity’s preliminary assessment, the Standard will not have an impact on the transactions and balances recognized in the financial statements when it is first adopted for the year ending June 30, 2019 based on the financial assets and liabilities held by the group at the date of this report. Mandatory application date / Date of adoption by group - Must be applied for financial years commencing on or after January 1, 2018. Expected date of adoption by the group: July 1, 2018. • IFRS 15 Revenue from Contracts with Customers - The IASB has issued a new standard for the recognition of revenue. This will replace IAS18 which covers contracts for goods and services. The new standard is based on the principle that revenue is recognized when control of a good or service transfers to a customer; so the notion of control replaces the existing notion of risks and rewards. Impact - Based on the entity’s preliminary assessment in relation to our existing contracts at June 30, 2018, the Standard will not have a material impact on the transactions and balances recognized in the financial statements when it is first adopted for the year ending June 30, 2019 because the Company does not yet have material revenue. 1. SIGNIFICANT ACCOUNTING POLICIES continued Subsequent to year end, as announced to the market via the ASX on July 9, 2018, the Company entered into an agreement with Axovant Sciences. In accordance with the agreement, US$10m (AUD$13.5m) was received on July 19, 2018 and further funds will follow over the coming years. Benitec will undertake a detailed review of this contract to determine the exact impact of applying the new revenue recognition standard to this contract. The standard permits a modified retrospective approach for the adoption. Under this approach, entities will recognise transitional adjustments in retained earnings on the date of initial application (eg July 1, 2017), ie without restating the comparative period. They will only need to apply the new rules to contracts that are not completed as of the date of initial application. Mandatory application date / Date of adoption by Group - commencing on or after January 1, 2018. Expected date of adoption by the Group: July 1, 2018. • I FRS 16 Leases - The IASB has issued a new standard for the recognition of leases. This will replace IAS 17: Leases . The new standard introduces a single lessee accounting model that no longer requires leases to be classified as operating or financing. Other major changes include, the recognition of a right-to-use asset and liability, depreciation of right-to-use assets in line with IAS16: Property Plant and Equipment Impact - The entity has undertaken a detailed review and has concluded that there will be no material impact on its financial position on the transactions and balances recognized in the financial statements when it is first adopted for the year ending June 30, 2020 due to the immaterial size of leases entered into by the Company. The Company’s only lease is the lease on its head office and research and development facilities. Commitments are set out in note 21. Mandatory application date / Date of adoption by Group - Must be applied for financial years commencing on or after January 1, 2019. Expected date of adoption by the Group: July 1, 2019. There are no other standards that are not yet effective and that would be expected to have a material impact on the entity in the current or future reporting periods and on foreseeable future transactions. (d) Going concern The directors have prepared the financial statements on a going concern basis after taking into consideration the net loss for the year of $11.640m (2017: $5.690m) and the cash and cash equivalents balance of $16.085m (2017: $17.375m). The directors have recognized the capital raisings in the last 3 years, performed a review of the cash flow forecasts, considered the cash flow needs of the Group, and believe that there will be sufficient to maintain the going concern status of the Group. We anticipate that we will continue to incur losses for at least the next several years. We expect that our research and development and general and administrative expenses will continue at a similar rate. The financial report does not contain any adjustments to the amounts or classifications of recorded assets or liabilities that might be necessary if the Group does not continue as a going concern. The financial statements take no account of the consequences, if any, of the effects of unsuccessful product development or commercialisation, nor of the inability of the Group to obtain adequate funding in the future. (e) Parent entity information In accordance with the Corporations Act 2001, these financial statements present the results of the Group only. Supplementary information about the parent entity is disclosed in note 24. 1. SIGNIFICANT ACCOUNTING POLICIES continued (f) Principles of consolidation The consolidated financial statements incorporate the assets and liabilities of all subsidiaries of Benitec Biopharma Limited ('Company' or 'parent entity') as at June 30, 2018 and the results of all subsidiaries for the year then ended. Benitec Biopharma Limited and its subsidiaries together are referred to in these financial statements as the 'Group'. Subsidiaries are all those entities over which the Group has control. The Group controls an entity when it is exposed to, or has rights to, variable returns from its involvement with the entity and has the ability to affect those returns through its power to direct the activities of the entity. Subsidiaries are fully consolidated from the date on which control is transferred to the Group. They are de-consolidated from the date that control ceases. The Company’s 100% owned subsidiary, Tacere Therapeutics, Inc. has a 31 December year end. The Company is reviewing the appropriate time to align the subsidiary year end to the parent’s year end. For consolidation purposes Tacere prepares financial statements for the 12 month period ended 30 June that are used to consolidate into the group accounts. Intercompany transactions, balances and unrealised gains on transactions between entities in the Group are eliminated. Unrealised losses are also eliminated unless the transaction provides evidence of the impairment of the asset transferred. Accounting policies of subsidiaries have been changed where necessary to ensure consistency with the policies adopted by the Group. The acquisition of subsidiaries is accounted for using the acquisition method of accounting. A change in ownership interest, without the loss of control, is accounted for as an equity transaction, where the difference between the consideration transferred and the book value of the share of the non-controlling interest acquired is recognized directly in equity attributable to the parent. Where the Group loses control over a subsidiary, it derecognises the assets including goodwill, liabilities and non-controlling interest in the subsidiary together with any cumulative translation differences recognized in equity. The Group recognises the fair value of the consideration received and the fair value of any investment retained together with any gain or loss in profit or loss. (g) Operating segments Operating segments are presented using the 'management approach', where the information presented is on the same basis as the internal reports provided to the Chief Operating Decision Makers ('CODM'). The CODM is responsible for the allocation of resources to operating segments and assessing their performance. (h) Foreign currency translation The financial statements are presented in Australian dollars, which is Benitec Biopharma Limited's functional and presentation currency. Foreign currency transactions Foreign currency transactions are translated into Australian dollars using the exchange rates prevailing at the dates of the transactions. Foreign exchange gains and losses resulting from the settlement of such transactions and from the translation at financial year-end exchange rates of monetary assets and liabilities denominated in foreign currencies are recognized in profit or loss. Foreign operations The assets and liabilities of foreign operations are translated into Australian dollars using the exchange rates at the reporting date. The revenues and expenses of foreign operations are translated into Australian dollars using the average exchange rates, which approximate the rates at the dates of the transactions, for the period. All resulting foreign exchange differences are recognized in other comprehensive income through the foreign currency reserve in equity. The foreign currency reserve is recognized in profit or loss when the foreign operation or net investment is disposed of. 1. SIGNIFICANT ACCOUNTING POLICIES continued (i) Revenue recognition Revenue is recognized when it is probable that the economic benefit will flow to the Group and the revenue can be reliably measured. Revenue is measured at the fair value of the consideration received or receivable. Licensing revenue and royalties Revenue from the granting of licenses is recognized in accordance with the terms of the relevant agreements and is usually recognized on an accruals basis, unless the substance of the agreement provides evidence that it is more appropriate to recognise revenue on some other systematic rational basis. Interest Interest revenue is recognized as interest accrues using the effective interest method. This is a method of calculating the amortised cost of a financial asset and allocating the interest income over the relevant period using the effective interest rate, which is the rate that exactly discounts estimated future cash receipts through the expected life of the financial asset to the net carrying amount of the financial asset. (j) Government research and development grants Government grants are recognized at fair value where there is reasonable assurance that the grant will be received and all grant conditions will be met. Grants relating to expense items are recognized as income over the periods necessary to match the grant costs they are compensating. Grants relating to assets are credited to deferred income at fair value and are credited to income over the expected useful life of the asset on a straight-line basis. Grant income is generated through the Australian federal government’s Research and Development Tax Incentive program, under which the government provides a cash refund for the 43.5% (2017 43.5%) of eligible research and development expenditures. Grants are recorded when a reliable estimate can be made. In the twelve months ended June 30, 2018 the Company estimated the grant income that will be receivable following the lodgement of the 2018 tax return. Previously the grant income was only taken up on the lodgement of the previous year’s tax return, which was the time at which it was considered a reliable estimate could be made. (k) Income tax The income tax expense or benefit for the period is the tax payable on that period's taxable income based on the applicable income tax rate for each jurisdiction, adjusted by the changes in deferred tax assets and liabilities attributable to temporary differences, unused tax losses and the adjustment recognized for prior periods, where applicable. Deferred tax assets and liabilities are recognized for temporary differences at the tax rates expected to be applied when the assets are recovered, or liabilities are settled, based on those tax rates that are enacted or substantively enacted, except for: • When the deferred income tax asset or liability arises from the initial recognition of goodwill or an asset or liability in a transaction that is not a business combination and that, at the time of the transaction, affects neither the accounting nor taxable profits; or • When the taxable temporary difference is associated with interests in subsidiaries, associates or joint ventures, and the timing of the reversal can be controlled, and it is probable that the temporary difference will not reverse in the foreseeable future. Deferred tax assets are recognized for deductible temporary differences and unused tax losses only if it is probable that future taxable amounts will be available to utilise those temporary differences and losses. 1. SIGNIFICANT ACCOUNTING POLICIES continued The carrying amount of recognized and unrecognized deferred tax assets are reviewed at each reporting date. Deferred tax assets recognized are reduced to the extent that it is no longer probable that future taxable profits will be available for the carrying amount to be recovered. Previously unrecognized deferred tax assets are recognized to the extent that it is probable that there are future taxable profits available to recover the asset. Deferred tax assets and liabilities are offset only where there is a legally enforceable right to offset current tax assets against current tax liabilities and deferred tax assets against deferred tax liabilities; and they relate to the same taxable authority on either the same taxable entity or different taxable entities which intend to settle simultaneously. Benitec Biopharma Limited (the 'head entity') and its wholly-owned Australian subsidiaries have formed an income tax consolidated group under the tax consolidation regime. The head entity and each subsidiary in the tax consolidated group continue to account for their own current and deferred tax amounts. The tax consolidated group has applied the 'separate taxpayer within group' approach in determining the appropriate amount of taxes to allocate to members of the tax consolidated group. No tax sharing agreement has been entered between entities in the tax consolidated group. In addition to its own current and deferred tax amounts, the head entity also recognises the current tax liabilities (or assets) and the deferred tax assets arising from unused tax losses and unused tax credits assumed from each subsidiary in the tax consolidated group. (l) Current and non-current classification Assets and liabilities are presented in the statement of financial position based on current and non-current classification. An asset is classified as current when: it is either expected to be realised or intended to be sold or consumed in normal operating cycle; it is held primarily for the purpose of trading; it is expected to be realised within 12 months after the reporting period; or the asset is cash or cash equivalent unless restricted from being exchanged or used to settle a liability for at least 12 months after the reporting period. All other assets are classified as non-current. A liability is classified as current when: it is either expected to be settled in normal operating cycle; it is held primarily for the purpose of trading; it is due to be settled within 12 months after the reporting period; or there is no unconditional right to defer the settlement of the liability for at least 12 months after the reporting period. All other liabilities are classified as non-current. Deferred tax assets and liabilities are always classified as non-current. (m) Cash and cash equivalents Cash and cash equivalents includes cash on hand, deposits held at call with financial institutions, other short-term, highly liquid investments with original maturities of three months or less that are readily convertible to known amounts of cash and which are subject to an insignificant risk of changes in value. (n) Trade and other receivables Other receivables are recognized at amortised cost, less any provision for impairment. (o) Investments and other financial assets Investments and other financial assets are initially measured at fair value. Transaction costs are included as part of the initial measurement, except for financial assets at fair value through profit or loss. They are subsequently measured at either amortised cost or fair value depending on their classification. Classification is determined based on the purpose of the acquisition and subsequent reclassification to other categories is restricted. 1. SIGNIFICANT ACCOUNTING POLICIES continued Financial assets are derecognized when the rights to receive cash flows from the financial assets have expired or have been transferred and the Group has transferred substantially all the risks and rewards of ownership. Loans and receivables Loans and receivables are non-derivative financial assets with fixed or determinable payments that are not quoted in an active market. They are carried at amortised cost using the effective interest rate method. Gains and losses are recognized in profit or loss when the asset is derecognized or impaired. Impairment of financial assets The Group assesses at the end of each reporting period whether there is any objective evidence that a financial asset or group of financial assets is impaired. Objective evidence includes significant financial difficulty of the issuer or obligor; a breach of contract such as default or delinquency in payments; the lender granting to a borrower concessions due to economic or legal reasons that the lender would not otherwise do; it becomes probable that the borrower will enter bankruptcy or other financial reorganisation; the disappearance of an active market for the financial asset; or observable data indicating that there is a measurable decrease in estimated future cash flows. The amount of the impairment allowance for loans and receivables carried at amortised cost is the difference between the asset's carrying amount and the present value of estimated future cash flows, discounted at the original effective interest rate. If there is a reversal of impairment, the reversal cannot exceed the amortised cost that would have been recognized had the impairment not been made and is reversed to profit or loss. (p) Plant and equipment Plant and equipment is stated at historical cost less accumulated depreciation and impairment. Historical cost includes expenditure that is directly attributable to the acquisition of the items. Depreciation is calculated on a straight-line basis to write off the net cost of each item of property, plant and equipment (excluding land) over their expected useful lives as follows: Leasehold improvements period of the lease term Plant and equipment 3-7 years The residual values, useful lives and depreciation methods are reviewed, and adjusted if appropriate, at each reporting date. An item of plant and equipment is derecognized upon disposal or when there is no future economic benefit to the Group. Gains and losses between the carrying amount and the disposal proceeds are taken to profit or loss. (q) Leases The determination of whether an arrangement is or contains a lease is based on the substance of the arrangement and requires an assessment of whether the fulfilment of the arrangement is dependent on the use of a specific asset or assets and the arrangement conveys a right to use the asset. (r) Impairment of non-financial assets Other intangible assets that have an indefinite useful life are not subject to amortisation and are tested annually for impairment, or more frequently if events or changes in circumstances indicate that they might be impaired. Other non-financial assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. An impairment loss is recognized for the amount by which the asset's carrying amount exceeds its recoverable amount. 1. SIGNIFICANT ACCOUNTING POLICIES continued Recoverable amount is the higher of an asset's fair value less costs of disposal and value-in-use. The value-in-use is the present value of the estimated future cash flows relating to the asset using a pre-tax discount rate specific to the asset or cash-generating unit to which the asset belongs. Assets that do not have independent cash flows are grouped together to form a cash-generating unit. (s) Trade and other payables These amounts represent liabilities for goods and services provided to the Group prior to the end of the financial year and which are unpaid. Due to their short-term nature, they are measured at amortised cost and are not discounted. The amounts are unsecured and are usually paid within 30 days of recognition. (t) Employee benefits Short-term employee benefits Liabilities for wages and salaries and other employee benefits expected to be settled within 12 months of the reporting date are measured at the amounts expected to be paid when the liabilities are settled. Other long-term employee benefits Employee benefits not expected to be settled within 12 months of the reporting date are measured as the present value of expected future payments to be made in respect of services provided by employees up to the reporting date using the projected unit credit method. Consideration is given to expected future wage and salary levels, experience of employee departures and periods of service. Expected future payments are discounted using market yields at the reporting date on high quality corporate bonds with terms to maturity and currency that match, as closely as possible, the estimated future cash outflows. Defined contribution superannuation expense Contributions to defined contribution superannuation plans are expensed in the period in which they are incurred. Share-based payments Equity-settled share-based compensation benefits are provided to directors and senior executives. The plan currently in place to provide these benefits is the Employee Share Option Plan ('ESOP'). Equity-settled transactions are awards of shares, or options over shares that are provided to employees in exchange for the rendering of services. The cost of equity-settled transactions are measured at fair value on grant date. Fair value is independently determined using Black-Scholes option pricing model that takes into account the exercise price, the term of the option, the impact of dilution, the share price at grant date and expected price volatility of the underlying share, the expected dividend yield and the risk free interest rate for the term of the option, together with non-vesting conditions that do not determine whether the Group receives the services that entitle the employees to receive payment. No account is taken of any other vesting conditions. The cost of equity-settled transactions are recognized as an expense with a corresponding increase in equity over the vesting period. The cumulative charge to profit or loss is calculated based on the grant date fair value of the award, the best estimate of the number of awards that are likely to vest and the expired portion of the vesting period. The amount recognized in profit or loss for the period is the cumulative amount calculated at each reporting date less amounts already recognized in previous periods. 1. SIGNIFICANT ACCOUNTING POLICIES continued Market conditions are taken into consideration in determining fair value. Therefore any awards subject to market conditions are considered to vest irrespective of whether or not that market condition has been met, provided all other conditions are satisfied. If equity-settled awards are modified, as a minimum an expense is recognized as if the modification has not been made. An additional expense is recognized, over the remaining vesting period, for any modification that increases the total fair value of the share-based compensation benefit as at the date of modification. If the non-vesting condition is within the control of the Group or employee, the failure to satisfy the condition is treated as a cancellation. If the condition is not within the control of the Group or employee and is not satisfied during the vesting period, any remaining expense for the award is recognized over the remaining vesting period, unless the award is forfeited. If equity-settled awards are cancelled, it is treated as if it has vested on the date of cancellation, and any remaining expense is recognized immediately. If a new replacement award is substituted for the cancelled award, the cancelled and new award is treated as if they were a modification. The dilutive effect, if any, of outstanding options is reflected as additional share dilution in the computation of earnings per share. (u) Fair value measurement When an asset or liability, financial or non-financial, is measured at fair value for recognition or disclosure purposes, the fair value is based on the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date; and assumes that the transaction will take place either: in the principal market; or in the absence of a principal market, in the most advantageous market. Fair value is measured using the assumptions that market participants would use when pricing the asset or liability, assuming they act in their economic best interests. For non-financial assets, the fair value measurement is based on its highest and best use. Valuation techniques that are appropriate in the circumstances and for which sufficient data is available to measure fair value, are used, maximising the use of relevant observable inputs and minimising the use of unobservable inputs. (v) Issued capital Ordinary shares are classified as equity. Incremental costs directly attributable to the issue of new shares or options are shown in equity as a deduction, net of tax, from the proceeds. Costs related to an initial offering are expensed in the statement of profit or loss and other comprehensive income. (w) Earnings per share Basic earnings per share Basic earnings per share is calculated by dividing the profit attributable to the owners of Benitec Biopharma Limited, excluding any costs of servicing equity other than ordinary shares, by the weighted average number of ordinary shares outstanding during the financial year, adjusted for bonus elements in ordinary shares issued during the financial year. Diluted earnings per share Diluted earnings per share adjusts the figures used in the determination of basic earnings per share to take into account the after income tax effect of interest and other financing costs associated with dilutive potential ordinary shares and the weighted average number of shares assumed to have been issued for no consideration in relation to dilutive potential ordinary shares. 1. SIGNIFICANT ACCOUNTING POLICIES continued (x) Goods and Services Tax ('GST') and other similar taxes Revenues, expenses and assets are recognized net of the amount of associated GST, unless the GST incurred is not recoverable from the tax authority. In this case it is recognized as part of the cost of the acquisition of the asset or as part of the expense. Receivables and payables are stated inclusive of the amount of GST receivable or payable. The net amount of GST recoverable from, or payable to, the tax authority is included in other receivables or other payables in the statement of financial position. Cash flows are presented on a gross basis. The GST components of cash flows arising from investing or financing activities which are recoverable from, or payable to the tax authority, are presented as operating cash flows. Commitments and contingencies are disclosed net of the amount of GST recoverable from, or payable to, the tax authority. (y) Rounding of amounts The Parent entity has applied the relief available to it under ASIC Corporations (Rounding in Financial/Directors’ Reports) instrument 2016/191 and accordingly amounts in the financial statements and Directors Report have been rounded off to the nearest $1,000, or in certain cases, to the nearest dollars.

Critical Accounting Judgements,

Critical Accounting Judgements, Estimates and Assumptions	12 Months Ended
	Jun. 30, 2018
Disclosure Of Changes In Accounting Estimates [Abstract]
Critical Accounting Judgements, Estimates and Assumptions	2. CRITICAL ACCOUNTING JUDGEMENTS, ESTIMATES AND ASSUMPTIONS The preparation of the financial statements requires management to make judgements, estimates and assumptions that affect the reported amounts in the financial statements. Management continually evaluates its judgements and estimates in relation to assets, liabilities, contingent liabilities, revenue and expenses. Management bases its judgements, estimates and assumptions on historical experience and on other various factors, including expectations of future events, management believes to be reasonable under the circumstances. The resulting accounting judgements and estimates will seldom equal the related actual results. The judgements, estimates and assumptions that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities (refer to the respective notes) within the next financial year are discussed below. Research and development expenses Management does not consider the development programs to be sufficiently advanced to reliably determine the economic benefits and technical feasibility to justify capitalization of development costs. These costs have been recognized as an expense when incurred. Research and development expenses relate primarily to the cost of conducting clinical and pre-clinical trials. Clinical development costs are a significant component of research and development expenses. Estimates have been used in determining the expense liability under certain clinical trial contracts where services have been performed but not yet invoiced. Generally, the costs, and therefore estimates, associated with clinical trial contracts are based on the number of patients, drug administration cycles, the type of treatment and the outcome being the length of time before actual amounts can be determined will vary depending on length of the patient cycles and the timing of the invoices by the clinical trial partners. Research and development refundable tax offsets The Group accounts for the federal government research and development grant tax incentive when a reliable estimate of the amounts receivable can be made. In the year ended June 30, 2017 reporting period detailed reporting systems were implemented to allow for the first time a reliable estimate to be made of the grant income that is expected to be received for the current period. In determining the estimate management reviews historical claims, Government overseas findings enabling the claim of overseas expenditure and the allocation of staff and overheads costs within approved projects. Judgement is also applied in determining the eligibility of the activities undertaken in Australia and overseas. Grant Income for the year ended June 30, 2018 includes an estimate of Research and Development grant receivable for June 30, 2018 of $3,999k. (refer Note 4b). Share-based payment transactions The Group measures the cost of equity-settled transactions with employees by reference to the fair value of the equity instruments at the date at which they are granted. The fair value is determined by using either the Black-Scholes model taking into account the terms and conditions upon which the instruments were granted. The accounting estimates and assumptions relating to equity-settled share-based payments would have no impact on the carrying amounts of assets and liabilities within the next annual reporting period but may impact profit or loss and equity. Recovery of deferred tax assets Deferred tax assets are recognized for deductible temporary differences only if the Group considers it is probable that future taxable amounts will be available to utilise those temporary differences and losses. Given the Company’s and each individual entities’ history of recent losses, the Group has not recognized a deferred tax asset with regard to unused tax losses and other temporary differences, as it has not been determined whether the Company or its subsidiaries will generate sufficient taxable income against which the unused tax losses and other temporary differences can be utilized. Costs of capital raising Costs directly attributable to an equity transaction are held in the statement of financial position until the completion of the transaction. On completion, the costs will be applied against issued capital. Costs associated with abandoned or sub-optimal equity transactions are expensed to profit or loss in the year the transaction is determined to no longer be viable under existing conditions.

Operating Segments

Operating Segments	12 Months Ended
	Jun. 30, 2018
Disclosure Of Operating Segments [Abstract]
Operating Segments	3. OPERATING SEGMENTS The Group had only one business segment during the period, being the global commercialisation by licensing and partnering of patents and licences in biotechnology, with applications in biomedical research and human therapeutics. Business operations are conducted in Australia. However, there are controlled entities based in the USA and United Kingdom. The United Kingdom entity has no segment revenues, results or assets. Geographical Segments Geographical location Segment Revenues from External Customers Segment Results Carrying Amount of Segment Assets Jun 2018 Jun 2017 Jun 2018 Jun 2017 Jun 2018 Jun 2017 $’000 $’000 $’000 $’000 $’000 $’000 Australia 378 333 (11,733 ) (5,835 ) 19,639 21,580 United States of America — — 93 145 1,700 1,086 378 333 (11,640 ) (5,690 ) 21,339 22,666 Accounting Policies Segment revenues and expenses are directly attributable to the identified segments. Segment assets include all assets used by a segment and consist mainly of cash, receivables, inventories, intangibles and property, plant and equipment, net of any allowances, accumulated depreciation and amortisation. Segment liabilities include mainly accounts payable, employee entitlements, accrued expenses, provisions and borrowings. Deferred income tax provisions are not included in segment assets and liabilities.

Revenue and Other Income

Revenue and Other Income	12 Months Ended
	Jun. 30, 2018
Material Income And Expense [Abstract]
Revenue and Other Income	4. REVENUE AND OTHER INCOME (a) 2018 2017 2016 $’000 $’000 $’000 Licensing revenue and royalties 378 333 247 Interest 242 253 217 620 586 464 (b) Other income Australian Government R&D grants 3,999 10,507 3,590 Foreign exchange unrealized gain 87 — — Other 1 — — 4,087 10,507 3,590 There is no discernible seasonality in the operations of the consolidated entity.

Expenses

Expenses	12 Months Ended
	Jun. 30, 2018
Material Income And Expense [Abstract]
Expenses	5. EXPENSES Loss before income tax includes the following specific expenses: Depreciation Leasehold improvements 25 53 205 Plant and equipment 169 164 85 Total depreciation 194 217 290 Research and development Project expenses 6,219 6,456 12,240 Other IP related expenses 671 469 1,047 Total research and development 6,890 6,925 13,287 Employee benefits expense Defined contribution superannuation expense 241 240 280 Employee benefits expense excluding superannuation 4,853 4,775 6,003 5,094 5,015 6,283 Rental expense relating to operating leases Minimum lease payments 384 376 265

Income Tax Benefit

Income Tax Benefit	12 Months Ended
	Jun. 30, 2018
Major Components Of Tax Expense Income [Abstract]
Income Tax Benefit	6. INCOME TAX BENEFIT 2018 2017 2016 $’000 $’000 $’000 Income tax benefit Current tax — — — Aggregate income tax benefit — — — Numerical reconciliation of income tax benefit and tax at the statutory rate Loss before income tax benefit (11,640 ) (5,690 ) (24,778 ) Tax at the statutory tax rate of 27.5% (2017:27.5%)(2016:30%) (3,201 ) (1,565 ) (7,433 ) Tax effect amounts which are not deductible/(taxable) in calculating taxable income: R&D expenses 2,605 2,676 4,151 R&D incentive income (1,124 ) (2,889 ) (1,090 ) Legal expenses 70 154 59 Share-based payments 119 106 524 Timing differences utilised not previously recognised (196 ) (506 ) (277 ) Write off prepayment — — 540 Impact of foreign exchange rate differences — 2 46 (1,727 ) (2,022 ) (3,480 ) Tax losses not brought to account 1,727 2,022 3,480 Income tax benefit — — — The above potential tax benefit has not been recognized in the statement of financial position. These tax losses are recognized only if the consolidated entity considers it is probable that future taxable amounts will be available to utilise those temporary differences and losses. Tax losses for which no deferred tax asset has been recognised - Australia - Tax losses not recognised 61,471 60,382 53,031 - Capital losses not recognised 1,272 1,272 1,272 - Other deferred tax assets not recognised 627 2,776 4,225 63,370 64,430 58,528 Potential tax benefit of tax assets not recognised at 27.5% (2017:27.5%) (2016:30%) 17,427 17,718 17,558 Tax losses for which no deferred tax asset has been recognised - US (Tacere) - Tax losses not recognised 846 955 1,137 Potential tax benefit of tax assets not recognised at 34% - US 233 324 387 The above potential tax benefit, which excludes tax losses, for deductible temporary differences has not been recognized in the statement of financial position as the recovery of this benefit is uncertain.

Cash and Cash Equivalents

Cash and Cash Equivalents	12 Months Ended
	Jun. 30, 2018
Cash And Cash Equivalents [Abstract]
Cash and Cash Equivalents	7. CASH AND CASH EQUIVALENTS 2018 2017 $'000 $'000 Cash at bank 9,575 4,349 Cash on deposit 6,510 13,026 16,085 17,375

Other Financial Assets

Other Financial Assets	12 Months Ended
	Jun. 30, 2018
Disclosure Of Financial Assets [Abstract]
Other Financial Assets	8. OTHER FINANCIAL ASSETS 2018 2017 $'000 $'000 Market value of listed shares 30 — Security Deposit 100 100 130 100

Trade and Other Receivables

Trade and Other Receivables	12 Months Ended
	Jun. 30, 2018
Trade And Other Current Receivables [Abstract]
Trade and Other Receivables	9 . TRADE AND OTHER RECEIVABLES 2018 2017 $'000 $'000 Settlement Receivable — 109 R&D Grant Receivable 4,121 4,233 Other 134 64 4,255 4,406

Current Assets - Other

Current Assets - Other	12 Months Ended
	Jun. 30, 2018
Subclassifications Of Assets Liabilities And Equities [Abstract]
Current Assets - Other	10. CURRENT ASSETS - OTHER 2018 2017 $'000 $'000 Prepayments 425 281 425 281

Deposits Non-current

Deposits Non-current	12 Months Ended
	Jun. 30, 2018
Subclassifications Of Assets Liabilities And Equities [Abstract]
Deposits Non-current	11. DEPOSITS non - current 2018 2017 $'000 $'000 Other 125 59 125 59

Property, Plant and Equipment

Property, Plant and Equipment	12 Months Ended
	Jun. 30, 2018
Disclosure Of Property Plant And Equipment [Abstract]
Property, Plant and Equipment	12. PROPERTY, PLANT AND EQUIPMENT 2018 2017 $'000 $'000 Leasehold improvements - at cost 79 79 Less: Accumulated depreciation (44 ) (19 ) 35 60 Plant and equipment - at cost 975 889 Less: Accumulated depreciation (691 ) (504 ) 284 385 319 445 Reconciliations Reconciliations of the written down values at the beginning and end of the current and previous financial year are set out below: Leasehold Plant and improvement equipment Total $'000 $'000 $'000 Balance at June 30, 2016 44 462 506 Additions 74 97 171 Depreciation expense (53 ) (164 ) (217 ) FX loss (5 ) (10 ) (15 ) Balance at June 30, 2017 60 385 445 Additions — 86 86 Disposals — (27 ) (27 ) Depreciation expense (25 ) (169 ) (194 ) FX loss — 9 9 Balance at June 30, 2018 35 284 319

Trade and Other Payables

Trade and Other Payables	12 Months Ended
	Jun. 30, 2018
Trade And Other Payables [Abstract]
Trade and Other Payables	13. TRADE AND OTHER PAYABLES 2018 2017 $'000 $'000 Trade creditors 580 174 Sundry creditors and accrued expenses 1,796 745 2,376 919

Provisions

Provisions	12 Months Ended
	Jun. 30, 2018
Provisions [Abstract]
Provisions	14. Employee Benefits 146 179 Provision for make good 25 27 171 206

Issued Capital

Issued Capital	12 Months Ended
	Jun. 30, 2018
Disclosure Of Classes Of Share Capital [Abstract]
Issued Capital	15. ISSUED CAPITAL Issued capital 2018 2017 2018 2017 Shares Shares $'000 $'000 Ordinary shares - fully paid 257,029,426 205,142,734 164,087 155,580 Movements in ordinary share capital Details Date Shares Issue price $'000 $ Balance June 30, 2017 205,142,734 155,580 Issue of shares Highbridge May 8, 2018 15,444,020 0.17 2,625 Issue of shares Nant Capital May 31, 2018 29,305,819 0.17 4,982 Issue of shares Entitlement offer June 4, 2018 7,136,853 0.17 1,213 Share issue transaction costs (313 ) Balance June 30, 2018 257,029,426 164,087 The weighted average number of shares on issue during the twelve months to June 30, 2018 was 210,454,829 Ordinary shares Ordinary shares entitle the holder to participate in dividends and the proceeds on the winding up of the Company in proportion to the number of and amounts paid on the shares held. The fully paid ordinary shares have no par value and the Company does not have a limited amount of authorised capital. On a show of hands every member present at a meeting in person or by proxy shall have one vote and upon a poll each share shall have one vote. Benitec shares are listed on the Australian Securities Exchange and trade under the code BLT. Benitec shares trade on Nasdaq as American Depository Receipts (ADR) under the code BNTC. Each ADR represents 20 ordinary shares. Share buy-back There is no current on-market share buy-back. Capital risk management The Group's objectives when managing capital is to safeguard its ability to continue as a going concern, so that it can provide returns for shareholders and benefits for other stakeholders and to maintain an optimum capital structure to reduce the cost of capital. The capital structure of the Group consists of cash and cash equivalents and equity attributable to equity holders. Operating globally, the Group develops speciality pharmaceutical products. The overall strategy of the Group is to continue its drug development programs, which depends on selling assets and raising additional equity to fund the activities. The capital risk management policy remains unchanged from the prior year.

Reserves

Reserves	12 Months Ended
	Jun. 30, 2018
Disclosure Of Reserves Within Equity [Abstract]
Reserves	16. RESERVES 2018 2017 $'000 $'000 Foreign currency reserve (1,348 ) (1,285 ) Share-based payments reserve 2,840 2,959 1,492 1,674 Foreign currency reserve The reserve is used to recognise exchange differences arising from the translation of the financial statements of foreign operations to Australian dollars. Share-based payments reserve The reserve is used to recognise the value of equity benefits provided to employees and directors as part of their remuneration, and other parties as part of their compensation for services. Movements in reserves Movements in each class of reserve during the current and previous financial year are set out below: Foreign Share-based currency payments Total $'000 $'000 $'000 Balance at June 30, 2016 (1,319 ) 3,884 2,565 Foreign currency translation 34 — 34 Share-based payments — (925 ) (925 ) Balance at June 30, 2017 (1,285 ) 2,959 1,674 Foreign currency translation (63 ) — (63 ) Share-based payments — (119 ) (119 ) Balance at June 30, 2018 (1,348 ) 2,840 1,492

Accumulated losses

Accumulated losses	12 Months Ended
	Jun. 30, 2018
Retained Earnings [Abstract]
Accumulated Losses	17. ACCUMULATED LOSSES 2018 2017 $'000 $'000 Accumulated losses at the beginning of the financial year (135,748 ) (131,369 ) Loss after income tax benefit for the year (11,640 ) (5,690 ) Transfer from share-based payment reserve for expired options 553 1,311 Accumulated losses at the end of the financial year (146,835 ) (135,748 )

Dividends

Dividends	12 Months Ended
	Jun. 30, 2018
Disclosure Of Dividends [Abstract]
Dividends	18. DIVIDENDS There were no dividends paid, recommended or declared during the current or previous financial year.

Financial Instruments

Financial Instruments	12 Months Ended
	Jun. 30, 2018
Disclosure Of Financial Instruments [Abstract]
Financial Instruments	19. FINANCIAL INSTRUMENTS Financial risk management objectives The Group's activities expose it to a variety of financial risks: market risk (including foreign currency risk and interest rate risk) and liquidity risk. The Group’s principal financial instruments comprise receivables, payables, cash and short-term deposits. The Group manages its exposure to key financial risks, including interest rate and currency risk in accordance with the Company financial risk management policy. The objective of the policy is to protect the assets and provide a solid return. 2018 2017 $'000 $'000 Financial Assets Cash and cash equivalents 16,085 17,375 Trade and other receivables 4,255 4,406 Total Financial Assets 20,340 21,781 Financial Liabilities Trade and other payables 2,376 919 Total Financial Liabilities 2,376 919 Market risk Foreign currency risk The Group undertakes certain transactions denominated in foreign currency and is exposed to foreign currency risk through foreign exchange rate fluctuations. Foreign exchange risk arises from future commercial transactions and recognized financial assets and financial liabilities denominated in a currency that is not the entity's functional currency. The risk is measured using sensitivity analysis and cash flow forecasting. At the June 30, 2018 the Company held USD cash or cash equivalents of AUD$7.536m and trade payables and accruals of AUD$1.630m. Net USD exposure in AUD of $5.907m. Each 1 cent movement in the AUD/USD exchange rate has a +/- effect of AUD $82k on profit and net assets of the Company. Exposure to foreign exchange rates vary during the year depending on the volume of overseas transactions. Nonetheless the analysis above is considered to be appropriate of the Group’s exposure to currency risk. Interest rate risk The Group generates income from interest on surplus funds. At reporting date, the Group had the following assets exposed to Australian variable interest rate risk that are not designated in cash flow hedges. As at the reporting date, the Group had the following variable rate cash and cash equivalents outstanding: 2018 2017 Weighted average interest rate Balance Weighted average interest rate Balance % $'000 % $'000 Cash and cash equivalents 2 % 16,085 1 % 17,375 Net exposure to cash flow interest rate risk 16,085 17,375 Credit risk Credit risk refers to the risk that a counterparty will default on its contractual obligations resulting in financial loss to the Group. The maximum exposure to credit risk at the reporting date to recognized financial assets is the carrying amount, net of any provisions for impairment of those assets, as disclosed in the statement of financial position and notes to the financial statements. The Group does not hold any collateral. Liquidity risk Vigilant liquidity risk management requires the Group to maintain sufficient liquid assets (mainly cash and cash equivalents) to be able to pay debts as and when they become due and payable. The Group manages liquidity risk by maintaining adequate cash reserves and available borrowing facilities by continuously monitoring actual and forecast cash flows and matching the maturity profiles of financial assets and liabilities Remaining contractual maturities The following tables detail the Group's remaining contractual maturity for its financial instrument liabilities. The tables have been drawn up based on the undiscounted cash flows of financial liabilities based on the earliest date on which the financial liabilities are required to be paid. Weighted average interest rate 1 year or less Between 1 and 2 years Between 2 and 5 years Over 5 years Remaining contractual maturities 2018 % $'000 $'000 $'000 $'000 $'000 Non-derivatives Non-interest bearing Trade payables -% 580 — — — 580 Other payables -% 1,796 — — — 1,796 Total non-derivatives 2,376 — — — 2,376 2017 % $'000 $'000 $'000 $'000 $'000 Non-derivatives Non-interest bearing Trade payables -% 174 — — — 174 Other payables -% 745 — — — 745 Total non-derivatives 919 — — — 919 2016 % $'000 $'000 $'000 $'000 $'000 Non-derivatives Non-interest bearing Trade payables -% 538 — — — 538 Other payables -% 295 — — — 295 Total non-derivatives 833 — — — 833 The cash flows in the maturity analysis above are not expected to occur significantly earlier than contractually disclosed above. Fair value of financial instruments Unless otherwise stated, the carrying amounts of financial instruments reflect their fair value.

Remuneration of Auditors

Remuneration of Auditors	12 Months Ended
	Jun. 30, 2018
Auditors Remuneration [Abstract]
Remuneration of Auditors	20. REMUNERATION OF AUDITORS During the financial year the following fees were paid or payable for services provided by Grant Thornton Audit Pty Ltd, the auditor of the Company: 2018 2017 Audit services - Grant Thornton Audit Pty Ltd $ $ Audit or review of the financial statements 240,806 241,933 Other audit services - F1 consent 17,990 20,800 - F3 consent 6,660 9,561 Other services - Grant Thornton Audit Pty Ltd Tax compliance services 42,617 23,150 42,617 23,150 308,073 295,444

Commitments

Commitments	12 Months Ended
	Jun. 30, 2018
Disclosure Of Finance Lease And Operating Lease By Lessee [Abstract]
Commitments	21. COMMITMENTS 2018 2017 2016 $'000 $'000 $'000 Lease commitments - operating Committed at the reporting date but not recognised as liabilities, payable: Within one year 219 169 126 One to five years 293 89 98 512 258 224 Operating lease commitments includes contracted amounts for offices under non-cancellable operating leases expiring within 3 years with, in some cases, options to extend. The leases have various escalation clauses. On renewal, the terms of the leases are renegotiated. Parent entity Benitec Biopharma Limited is the parent entity. Subsidiaries Interests in subsidiaries are set out in note 25. Key management personnel Disclosures relating to key management personnel are set out in note 23 and the remuneration report in the directors' report.

Contingent Liabilities

Contingent Liabilities	12 Months Ended
	Jun. 30, 2018
Disclosure Of Contingent Liabilities [Abstract]
Contingent Liabilities	22. CONTINGENT LIABILITIES Under the terms of the sub-license agreement with NantWorks, the Company will be required to make a milestone payment to NantWorks of US$300k (AUD$405k) upon dosing of the last patient in the first Phase 2 clinical study using BB-401, the EGFR antisense product. The Company would be required to pay consideration to NantWorks, upon successful completion of subsequent regulatory and commercial milestones. Under the terms of a commercial license agreement with Oxford Expression Technologies (OET), the Company will be required to make a milestone payment to OET of GBP30,000 (AUD$53,543) upon entry into the clinic with BB-301.

Related Party Transactions

Related Party Transactions	12 Months Ended
	Jun. 30, 2018
Disclosure Of Transactions Between Related Parties [Abstract]
Related Party Transactions	23. RELATED PARTY TRANSACTIONS Parent entity Benitec Biopharma Limited is the parent entity. Key management personnel Disclosures relating to key management personnel are set out in Item 6B of this document. Compensation The aggregate compensation made to directors and other members of key management personnel of the Group is set out below: 2018 2017 2016 $ $ $ Short-term employee benefits 1,843,334 1,539,777 2,048,543 Post-employment benefits 89,780 76,623 55,630 Long-term benefits — 32,537 13,209 Share-based payments 257,001 418,986 1,011,851 2,190,115 2,067,923 3,129,233 The following transactions occurred with related parties: Payment for other expenses: Legal services paid / payable to Francis Abourizk Lightowlers, a law firm in which Mr Peter Francis is a partner and has a beneficial interest. 8,212 191,050 116,540 Payment for rent at Francis Abourizk Lightowlers law firm which Mr Peter Francis is a partner and has a beneficial interest — — 11,102 Consultancy fees for executive duties paid/payable to NewStar Ventures Ltd, a corporation in which Dr John Chiplin is a director and has a beneficial interest. — 32,133 165,983 Annabel West, the wife of Greg West, our former Chief Executive Officer, was employed as a part-time clerical and administrative assistant. 42,278 36,248 47,722 Receivable from and payable to related parties There were no trade receivables from or trade payables to related parties at the current and previous reporting date. Loans to/from related parties There were no loans to or from related parties at the current and previous reporting date. 23. RELATED PARTY TRANSACTIONS continued Terms and conditions All transactions were made on normal commercial terms and conditions and at market rates.

Parent Entity Information

Parent Entity Information	12 Months Ended
	Jun. 30, 2018
Disclosure Of Parent Entity Information [Abstract]
Parent Entity Information	24. PARENT ENTITY INFORMATION Set out below is the supplementary information about the parent entity. 2018 2017 $'000 $'000 Statement of profit or loss and other comprehensive income Loss after income tax (13,566 ) (5,835 ) Total comprehensive income (13,566 ) (5,835 ) Statement of financial position Total current assets 19,461 21,421 Total assets 19,639 22,868 Total current liabilities 2,351 969 Total liabilities 2,399 1,004 Equity Issued capital 164,087 155,580 Share-based payments reserve 2,840 2,959 Accumulated losses (149,687 ) (136,675 ) Total equity 17,240 21,864 Guarantees entered into by the parent entity in relation to the debts of its subsidiaries The parent entity had no guarantees in relation to the debts of its subsidiaries as at June 30, 2018 and June 30, 2017. Contingent liabilities The parent entity had no contingent liabilities as at June 30, 2018 (2017: nil), other than the contingent liabilities described as belonging to the parent entity in note 22. Capital commitments - Property, plant and equipment The parent entity had no capital commitments for property, plant and equipment as at June 30, 2018 and June 30, 2017. Significant accounting policies The accounting policies of the parent entity are consistent with those of the Group, as disclosed in note 1, except for the following: • Investments in subsidiaries are accounted for at cost, less any impairment, in the parent entity. • Dividends received from subsidiaries are recognized as other income by the parent entity and its receipt may be an indicator of an impairment of the investment.

Interests in Subsidiaries

Interests in Subsidiaries	12 Months Ended
	Jun. 30, 2018
Disclosure Of Significant Investments In Subsidiaries [Abstract]
Interests in Subsidiaries	25. INTERESTS IN SUBSIDIARIES The consolidated financial statements incorporate the assets, liabilities and results of the following subsidiaries in accordance with the accounting policy described in note 1: Principal place of business / 2018 2017 2016 Name Country of incorporation % % % Benitec Limited United Kingdom 100% 100% 100% Benitec Australia Limited (subsidiary of Benitec Limited) Australia 100% 100% 100% Benitec, Inc. USA 100% 100% 100% Benitec LLC (subsidiary of Benitec Inc) USA 100% 100% 100% RNAi Therapeutics, Inc. USA 100% 100% 100% Tacere Therapeutics, Inc.* USA 100% 100% 100% All companies in the Group adopt the same accounting policies. * Note Tacere year end is 31 December which was the year end date when the Company was acquired.

Events After the Reporting Peri

Events After the Reporting Period	12 Months Ended
	Jun. 30, 2018
Disclosure Of Nonadjusting Events After Reporting Period [Abstract]
Events After the Reporting Period	26. EVENTS AFTER THE REPORTING PERIOD On July 9, 2018, it was announced that a license was entered into with Axovant Sciences (“Axovant”) granting the exclusive global rights for BB-301 (now named AXO-AAV-OPMD) intended for the treatment of oculopharyngeal muscular dystrophy (OPMD), as well as entering into a fully funded research collaboration for the development of five additional gene therapy products in neurological disorders. Under the terms of the agreement, Benitec will receive an upfront cash payment of US$10m (AUD $13.5m) and additional cash payments totalling US$17.5m (AUD$23.6m) upon completion of four specific near-term manufacturing, regulatory and clinical milestones. Axovant has been granted worldwide rights to AXO-AAV-OPMD and will assume all future development costs. The total potential value of all of the development, regulatory and commercial milestones achievable by Benitec, of which there are eight milestones including the four near-term to achieve all eight milestones and thus realize the maximum amount of US$187.5m (AUD$253.3m). There can be no assurance as to the total amount of payments that the Company will actually receive or when they will be received. Importantly, upon commercialisation, Benitec will retain 30% of the net profits on worldwide sales of AXO-AAV-OPMD. No other matter or circumstance has arisen since June 30, 2018 that has significantly affected, or may significantly affect the Group's operations, the results of those operations, or the Group's state of affairs in future financial years.

Reconciliation of Loss after In

Reconciliation of Loss after Income Tax to Net Cash Used in Operating Activities	12 Months Ended
	Jun. 30, 2018
Reconciliation Of Loss After Income Tax To Net Cash Used In Operating Activities [Abstract]
Reconciliation of Loss after Income Tax to Net Cash Used in Operating Activities	27. RECONCILIATION OF LOSS AFTER INCOME TAX TO NET CASH USED IN OPERATING ACTIVITIES 2018 $'000 2017 $'000 2016 $'000 Loss after income tax benefit for the year (11,640 ) (5,690 ) (24,778 ) Adjustments for: Loss on disposal of fixed assets 1 6 — Depreciation and amortisation 194 217 290 Share-based payments 434 386 1,746 Net unrealised Foreign exchange (82 ) 242 506 Issue of ordinary shares to Biomics — — 500 Impairment of prepayment — — 1,800 Change in operating assets and liabilities: Increase in trade and other receivables 72 814 (854 ) (Decrease) in other current assets (121 ) (182 ) 1,178 Increase in trade and other payables 1,259 114 (623 ) (Decrease) in R&D grant receivable 112 (4,233 ) — (Decrease) in employee benefits (23 ) (3 ) 27 Increase in provision — 25 — Net cash used in operating activities (9,794 ) (8,304 ) (20,208 )

Earnings Per Share

Earnings Per Share	12 Months Ended
	Jun. 30, 2018
Earnings Per Share [Abstract]
Earnings Per Share	28. EARNINGS PER SHARE Loss after income tax attributable to the owners of Benitec Biopharma Limited (11,640 ) (5,690 ) (24,778 ) Number Number Number Weighted average number of ordinary shares used in calculating basic earnings per share 210,454,829 175,433,909 142,312,486 Weighted average number of ordinary shares used in calculating diluted earnings per share 210,454,829 175,433,909 142,312,486 Cents Cents Cents Basic (loss) per share (5.53 ) (3.24 ) (17.41 ) Diluted (loss) per share (5.53 ) (3.24 ) (17.41 ) Outstanding options (see note 29) to acquire ordinary shares are not considered dilutive for the years ended June 30, 2018 and June 30, 2017.

Share-based Payments

Share-based Payments	12 Months Ended
	Jun. 30, 2018
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Abstract]
Share-based Payments	29. SHARE-BASED PAYMENTS Benitec Biopharma Limited Employees Share Option Plan (ESOP): Description of plan The Group may from time to time issue employee’s options to acquire shares in the parent at a fixed price. Each option when exercised entitles the option holder to one share in the Parent Company. Options are exercisable on or before an expiry date, do not carry any voting or dividend rights and are not transferable except on death of the option holder. The following table shows the number and weighted average exercise price (WAEP) of share options issued under the ESOP: 2018 2018 2017 2017 2016 2016 Number WAEP Number WAEP Number WAEP $ $ $ Outstanding at the beginning of the year 9,724,000 0.832 12,220,000 1.079 12,500,000 1.234 Granted during the year 19,950,000 0.218 2,200,000 0.166 6,720,000 0.770 Exercised during the year — — — — — — Lapsed or forfeited during the year (5,196,668 ) 0.426 (4,696,000 ) 1.164 (7,000,000 ) 1.060 Outstanding at the end of the year 24,477,332 0.416 9,724,000 0.832 12,220,000 1.079 Options exercisable at the end of the year 6,527,333 6,497,333 8,292,000 Details of ESOP share options outstanding as at end of year: 2018 2017 2016 Exercise Number Number Number Grant date Expiry date price Under option Under option Under option September 26, 2011* September 26, 2016 $ 1.250 — — 2,800,000 November 17, 2012 ** November 17, 2017 $ 1.250 — 400,000 600,000 February 7, 2012** February 7, 2017 $ 1.250 — — 156,000 November 6, 2012** November 6, 2017 $ 1.250 — — 400,000 November 10, 2013 * May 18 2018 $ 0.620 — 400,000 400,000 August 22, 2013 ** August 22 2018 $ 1.250 480,000 480,000 480,000 May 15, 2014 ** May 15, 2019 $ 1.500 90,000 180,000 180,000 December 17, 2014 ** December 17, 2019 $ 1.250 2,334,000 2,334,000 2,634,000 May 6, 2015 ** May 6, 2020 $ 1.250 650,000 650,000 650,000 November 12, 2015* November 12, 2020 $ 0.770 2,240,000 3,080,000 3,920,000 August 9, 2016** August 9, 2021 $ 0.167 1,466,666 2,200,000 — July 17, 2017** July 17, 2022 $ 0.196 6,566,666 — — April 11, 2018** April 11, 2023 $ 0.298 650,000 — — June 26, 2018** June 26, 2023 $ 0.228 10,000,000 — — 24,477,332 9,724,000 12,220,000 * Non-Executive Directors options ** ESOP options 29. SHARE-BASED PAYMENTS continued The weighted average remaining life of the options issued under the ESOP at June 30, 2018 was 3 years and 10 months (2017: 2 years and 10 months, 2016: 2 years and 7 months). For the options granted during the year, the valuation model inputs used to determine the fair value at the grant date are as follows: Grant date Expiry date Share price Exercise Expected * Dividend Risk-free Fair value at grant date price volatility yield interest rate at grant date 17/07/2017 17/07/2022 $ 0.130 $ 0.196 100.01 % —% 2.370 % $ 0.091 11/04/2018 11/04/2023 $ 0.200 $ 0.298 101.43 % —% 2.373 % $ 0.141 26/06/2018 26/06/2023 $ 0.145 $ 0.228 100.31 % —% 2.303 % $ 0.100 Total expenses arising from share-based payment transactions recognized during the period as part of employee benefit expense were $0.434m (2017: $0.386m). * expected volatility was determined with reference to the Benitec share price based on historical volatility

Significant Accounting Polici_2

Significant Accounting Policies (Policies)	12 Months Ended
	Jun. 30, 2018
Disclosure Of Significant Accounting Policies [Abstract]
Basis of preparation	(a) Basis of preparation These general purpose financial statements have been prepared in accordance with Australian Accounting Standards and Interpretations issued by the Australian Accounting Standards Board ('AASB') and the Corporations Act 2001, as appropriate for for-profit oriented entities. These financial statements also comply with International Financial Reporting Standards as issued by the International Accounting Standards Board ('IASB'). Historical cost convention The financial statements have been prepared under the historical cost convention. Critical accounting estimates The preparation of the financial statements requires the use of certain critical accounting estimates. It also requires management to exercise its judgement in the process of applying the Group's accounting policies. The areas involving a higher degree of judgement or complexity, or areas where assumptions and estimates are significant to the financial statements, are disclosed in note 2.
New, revised or amending Accounting Standards and Interpretations adopted	(b) New, revised or amending Accounting Standards and Interpretations adopted In the current year the Group has adopted all of the new, revised or amended Accounting Standards and interpretations issued by the Australian Accounting Standards Board (AASB) that were mandatory for current financial year.
New Accounting Standards and Interpretations not yet mandatory or early adopted	(c) New Accounting Standards and Interpretations not yet mandatory or early adopted Certain new accounting standards and interpretations have been published that are not mandatory for June 30, 2018 reporting periods and have not been early adopted by the group. The group’s assessment of the impact of these new standards and interpretations is set out below. • IFRS 9 Financial Instruments - addresses the classification, measurement and derecognition of financial assets and financial liabilities and introduces new rules for hedge accounting. In December 2014, the IASB made further changes to the classification and measurement rules and also introduced a new impairment model. These latest amendments now complete the new financial instruments standard. Impact - Based on the entity’s preliminary assessment, the Standard will not have an impact on the transactions and balances recognized in the financial statements when it is first adopted for the year ending June 30, 2019 based on the financial assets and liabilities held by the group at the date of this report. Mandatory application date / Date of adoption by group - Must be applied for financial years commencing on or after January 1, 2018. Expected date of adoption by the group: July 1, 2018. • IFRS 15 Revenue from Contracts with Customers - The IASB has issued a new standard for the recognition of revenue. This will replace IAS18 which covers contracts for goods and services. The new standard is based on the principle that revenue is recognized when control of a good or service transfers to a customer; so the notion of control replaces the existing notion of risks and rewards. Impact - Based on the entity’s preliminary assessment in relation to our existing contracts at June 30, 2018, the Standard will not have a material impact on the transactions and balances recognized in the financial statements when it is first adopted for the year ending June 30, 2019 because the Company does not yet have material revenue. Subsequent to year end, as announced to the market via the ASX on July 9, 2018, the Company entered into an agreement with Axovant Sciences. In accordance with the agreement, US$10m (AUD$13.5m) was received on July 19, 2018 and further funds will follow over the coming years. Benitec will undertake a detailed review of this contract to determine the exact impact of applying the new revenue recognition standard to this contract. The standard permits a modified retrospective approach for the adoption. Under this approach, entities will recognise transitional adjustments in retained earnings on the date of initial application (eg July 1, 2017), ie without restating the comparative period. They will only need to apply the new rules to contracts that are not completed as of the date of initial application. Mandatory application date / Date of adoption by Group - commencing on or after January 1, 2018. Expected date of adoption by the Group: July 1, 2018. • I FRS 16 Leases - The IASB has issued a new standard for the recognition of leases. This will replace IAS 17: Leases . The new standard introduces a single lessee accounting model that no longer requires leases to be classified as operating or financing. Other major changes include, the recognition of a right-to-use asset and liability, depreciation of right-to-use assets in line with IAS16: Property Plant and Equipment Impact - The entity has undertaken a detailed review and has concluded that there will be no material impact on its financial position on the transactions and balances recognized in the financial statements when it is first adopted for the year ending June 30, 2020 due to the immaterial size of leases entered into by the Company. The Company’s only lease is the lease on its head office and research and development facilities. Commitments are set out in note 21. Mandatory application date / Date of adoption by Group - Must be applied for financial years commencing on or after January 1, 2019. Expected date of adoption by the Group: July 1, 2019. There are no other standards that are not yet effective and that would be expected to have a material impact on the entity in the current or future reporting periods and on foreseeable future transactions.
Going concern	(d) Going concern The directors have prepared the financial statements on a going concern basis after taking into consideration the net loss for the year of $11.640m (2017: $5.690m) and the cash and cash equivalents balance of $16.085m (2017: $17.375m). The directors have recognized the capital raisings in the last 3 years, performed a review of the cash flow forecasts, considered the cash flow needs of the Group, and believe that there will be sufficient to maintain the going concern status of the Group. We anticipate that we will continue to incur losses for at least the next several years. We expect that our research and development and general and administrative expenses will continue at a similar rate. The financial report does not contain any adjustments to the amounts or classifications of recorded assets or liabilities that might be necessary if the Group does not continue as a going concern. The financial statements take no account of the consequences, if any, of the effects of unsuccessful product development or commercialisation, nor of the inability of the Group to obtain adequate funding in the future.
Parent entity information	(e) Parent entity information In accordance with the Corporations Act 2001, these financial statements present the results of the Group only. Supplementary information about the parent entity is disclosed in note 24.
Principles of consolidation	(f) Principles of consolidation The consolidated financial statements incorporate the assets and liabilities of all subsidiaries of Benitec Biopharma Limited ('Company' or 'parent entity') as at June 30, 2018 and the results of all subsidiaries for the year then ended. Benitec Biopharma Limited and its subsidiaries together are referred to in these financial statements as the 'Group'. Subsidiaries are all those entities over which the Group has control. The Group controls an entity when it is exposed to, or has rights to, variable returns from its involvement with the entity and has the ability to affect those returns through its power to direct the activities of the entity. Subsidiaries are fully consolidated from the date on which control is transferred to the Group. They are de-consolidated from the date that control ceases. The Company’s 100% owned subsidiary, Tacere Therapeutics, Inc. has a 31 December year end. The Company is reviewing the appropriate time to align the subsidiary year end to the parent’s year end. For consolidation purposes Tacere prepares financial statements for the 12 month period ended 30 June that are used to consolidate into the group accounts. Intercompany transactions, balances and unrealised gains on transactions between entities in the Group are eliminated. Unrealised losses are also eliminated unless the transaction provides evidence of the impairment of the asset transferred. Accounting policies of subsidiaries have been changed where necessary to ensure consistency with the policies adopted by the Group. The acquisition of subsidiaries is accounted for using the acquisition method of accounting. A change in ownership interest, without the loss of control, is accounted for as an equity transaction, where the difference between the consideration transferred and the book value of the share of the non-controlling interest acquired is recognized directly in equity attributable to the parent. Where the Group loses control over a subsidiary, it derecognises the assets including goodwill, liabilities and non-controlling interest in the subsidiary together with any cumulative translation differences recognized in equity. The Group recognises the fair value of the consideration received and the fair value of any investment retained together with any gain or loss in profit or loss.
Operating segments	(g) Operating segments Operating segments are presented using the 'management approach', where the information presented is on the same basis as the internal reports provided to the Chief Operating Decision Makers ('CODM'). The CODM is responsible for the allocation of resources to operating segments and assessing their performance.
Foreign currency translation	(h) Foreign currency translation The financial statements are presented in Australian dollars, which is Benitec Biopharma Limited's functional and presentation currency. Foreign currency transactions Foreign currency transactions are translated into Australian dollars using the exchange rates prevailing at the dates of the transactions. Foreign exchange gains and losses resulting from the settlement of such transactions and from the translation at financial year-end exchange rates of monetary assets and liabilities denominated in foreign currencies are recognized in profit or loss. Foreign operations The assets and liabilities of foreign operations are translated into Australian dollars using the exchange rates at the reporting date. The revenues and expenses of foreign operations are translated into Australian dollars using the average exchange rates, which approximate the rates at the dates of the transactions, for the period. All resulting foreign exchange differences are recognized in other comprehensive income through the foreign currency reserve in equity. The foreign currency reserve is recognized in profit or loss when the foreign operation or net investment is disposed of.
Revenue recognition	(i) Revenue recognition Revenue is recognized when it is probable that the economic benefit will flow to the Group and the revenue can be reliably measured. Revenue is measured at the fair value of the consideration received or receivable. Licensing revenue and royalties Revenue from the granting of licenses is recognized in accordance with the terms of the relevant agreements and is usually recognized on an accruals basis, unless the substance of the agreement provides evidence that it is more appropriate to recognise revenue on some other systematic rational basis. Interest Interest revenue is recognized as interest accrues using the effective interest method. This is a method of calculating the amortised cost of a financial asset and allocating the interest income over the relevant period using the effective interest rate, which is the rate that exactly discounts estimated future cash receipts through the expected life of the financial asset to the net carrying amount of the financial asset.
Government research and development grants	(j) Government research and development grants Government grants are recognized at fair value where there is reasonable assurance that the grant will be received and all grant conditions will be met. Grants relating to expense items are recognized as income over the periods necessary to match the grant costs they are compensating. Grants relating to assets are credited to deferred income at fair value and are credited to income over the expected useful life of the asset on a straight-line basis. Grant income is generated through the Australian federal government’s Research and Development Tax Incentive program, under which the government provides a cash refund for the 43.5% (2017 43.5%) of eligible research and development expenditures. Grants are recorded when a reliable estimate can be made. In the twelve months ended June 30, 2018 the Company estimated the grant income that will be receivable following the lodgement of the 2018 tax return. Previously the grant income was only taken up on the lodgement of the previous year’s tax return, which was the time at which it was considered a reliable estimate could be made.
Income tax	(k) Income tax The income tax expense or benefit for the period is the tax payable on that period's taxable income based on the applicable income tax rate for each jurisdiction, adjusted by the changes in deferred tax assets and liabilities attributable to temporary differences, unused tax losses and the adjustment recognized for prior periods, where applicable. Deferred tax assets and liabilities are recognized for temporary differences at the tax rates expected to be applied when the assets are recovered, or liabilities are settled, based on those tax rates that are enacted or substantively enacted, except for: • When the deferred income tax asset or liability arises from the initial recognition of goodwill or an asset or liability in a transaction that is not a business combination and that, at the time of the transaction, affects neither the accounting nor taxable profits; or • When the taxable temporary difference is associated with interests in subsidiaries, associates or joint ventures, and the timing of the reversal can be controlled, and it is probable that the temporary difference will not reverse in the foreseeable future. Deferred tax assets are recognized for deductible temporary differences and unused tax losses only if it is probable that future taxable amounts will be available to utilise those temporary differences and losses. The carrying amount of recognized and unrecognized deferred tax assets are reviewed at each reporting date. Deferred tax assets recognized are reduced to the extent that it is no longer probable that future taxable profits will be available for the carrying amount to be recovered. Previously unrecognized deferred tax assets are recognized to the extent that it is probable that there are future taxable profits available to recover the asset. Deferred tax assets and liabilities are offset only where there is a legally enforceable right to offset current tax assets against current tax liabilities and deferred tax assets against deferred tax liabilities; and they relate to the same taxable authority on either the same taxable entity or different taxable entities which intend to settle simultaneously. Benitec Biopharma Limited (the 'head entity') and its wholly-owned Australian subsidiaries have formed an income tax consolidated group under the tax consolidation regime. The head entity and each subsidiary in the tax consolidated group continue to account for their own current and deferred tax amounts. The tax consolidated group has applied the 'separate taxpayer within group' approach in determining the appropriate amount of taxes to allocate to members of the tax consolidated group. No tax sharing agreement has been entered between entities in the tax consolidated group. In addition to its own current and deferred tax amounts, the head entity also recognises the current tax liabilities (or assets) and the deferred tax assets arising from unused tax losses and unused tax credits assumed from each subsidiary in the tax consolidated group.
Current and non-current classification	(l) Current and non-current classification Assets and liabilities are presented in the statement of financial position based on current and non-current classification. An asset is classified as current when: it is either expected to be realised or intended to be sold or consumed in normal operating cycle; it is held primarily for the purpose of trading; it is expected to be realised within 12 months after the reporting period; or the asset is cash or cash equivalent unless restricted from being exchanged or used to settle a liability for at least 12 months after the reporting period. All other assets are classified as non-current. A liability is classified as current when: it is either expected to be settled in normal operating cycle; it is held primarily for the purpose of trading; it is due to be settled within 12 months after the reporting period; or there is no unconditional right to defer the settlement of the liability for at least 12 months after the reporting period. All other liabilities are classified as non-current. Deferred tax assets and liabilities are always classified as non-current.
Cash and cash equivalents	(m) Cash and cash equivalents Cash and cash equivalents includes cash on hand, deposits held at call with financial institutions, other short-term, highly liquid investments with original maturities of three months or less that are readily convertible to known amounts of cash and which are subject to an insignificant risk of changes in value.
Trade and other receivables	(n) Trade and other receivables Other receivables are recognized at amortised cost, less any provision for impairment.
Investments and other financial assets	(o) Investments and other financial assets Investments and other financial assets are initially measured at fair value. Transaction costs are included as part of the initial measurement, except for financial assets at fair value through profit or loss. They are subsequently measured at either amortised cost or fair value depending on their classification. Classification is determined based on the purpose of the acquisition and subsequent reclassification to other categories is restricted. Financial assets are derecognized when the rights to receive cash flows from the financial assets have expired or have been transferred and the Group has transferred substantially all the risks and rewards of ownership. Loans and receivables Loans and receivables are non-derivative financial assets with fixed or determinable payments that are not quoted in an active market. They are carried at amortised cost using the effective interest rate method. Gains and losses are recognized in profit or loss when the asset is derecognized or impaired. Impairment of financial assets The Group assesses at the end of each reporting period whether there is any objective evidence that a financial asset or group of financial assets is impaired. Objective evidence includes significant financial difficulty of the issuer or obligor; a breach of contract such as default or delinquency in payments; the lender granting to a borrower concessions due to economic or legal reasons that the lender would not otherwise do; it becomes probable that the borrower will enter bankruptcy or other financial reorganisation; the disappearance of an active market for the financial asset; or observable data indicating that there is a measurable decrease in estimated future cash flows. The amount of the impairment allowance for loans and receivables carried at amortised cost is the difference between the asset's carrying amount and the present value of estimated future cash flows, discounted at the original effective interest rate. If there is a reversal of impairment, the reversal cannot exceed the amortised cost that would have been recognized had the impairment not been made and is reversed to profit or loss.
Plant and equipment	(p) Plant and equipment Plant and equipment is stated at historical cost less accumulated depreciation and impairment. Historical cost includes expenditure that is directly attributable to the acquisition of the items. Depreciation is calculated on a straight-line basis to write off the net cost of each item of property, plant and equipment (excluding land) over their expected useful lives as follows: Leasehold improvements period of the lease term Plant and equipment 3-7 years The residual values, useful lives and depreciation methods are reviewed, and adjusted if appropriate, at each reporting date. An item of plant and equipment is derecognized upon disposal or when there is no future economic benefit to the Group. Gains and losses between the carrying amount and the disposal proceeds are taken to profit or loss.
Leases	(q) Leases The determination of whether an arrangement is or contains a lease is based on the substance of the arrangement and requires an assessment of whether the fulfilment of the arrangement is dependent on the use of a specific asset or assets and the arrangement conveys a right to use the asset.
Impairment of non-financial assets	(r) Impairment of non-financial assets Other intangible assets that have an indefinite useful life are not subject to amortisation and are tested annually for impairment, or more frequently if events or changes in circumstances indicate that they might be impaired. Other non-financial assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. An impairment loss is recognized for the amount by which the asset's carrying amount exceeds its recoverable amount. Recoverable amount is the higher of an asset's fair value less costs of disposal and value-in-use. The value-in-use is the present value of the estimated future cash flows relating to the asset using a pre-tax discount rate specific to the asset or cash-generating unit to which the asset belongs. Assets that do not have independent cash flows are grouped together to form a cash-generating unit.
Trade and other payables	(s) Trade and other payables These amounts represent liabilities for goods and services provided to the Group prior to the end of the financial year and which are unpaid. Due to their short-term nature, they are measured at amortised cost and are not discounted. The amounts are unsecured and are usually paid within 30 days of recognition.
Employee benefits	(t) Employee benefits Short-term employee benefits Liabilities for wages and salaries and other employee benefits expected to be settled within 12 months of the reporting date are measured at the amounts expected to be paid when the liabilities are settled. Other long-term employee benefits Employee benefits not expected to be settled within 12 months of the reporting date are measured as the present value of expected future payments to be made in respect of services provided by employees up to the reporting date using the projected unit credit method. Consideration is given to expected future wage and salary levels, experience of employee departures and periods of service. Expected future payments are discounted using market yields at the reporting date on high quality corporate bonds with terms to maturity and currency that match, as closely as possible, the estimated future cash outflows. Defined contribution superannuation expense Contributions to defined contribution superannuation plans are expensed in the period in which they are incurred. Share-based payments Equity-settled share-based compensation benefits are provided to directors and senior executives. The plan currently in place to provide these benefits is the Employee Share Option Plan ('ESOP'). Equity-settled transactions are awards of shares, or options over shares that are provided to employees in exchange for the rendering of services. The cost of equity-settled transactions are measured at fair value on grant date. Fair value is independently determined using Black-Scholes option pricing model that takes into account the exercise price, the term of the option, the impact of dilution, the share price at grant date and expected price volatility of the underlying share, the expected dividend yield and the risk free interest rate for the term of the option, together with non-vesting conditions that do not determine whether the Group receives the services that entitle the employees to receive payment. No account is taken of any other vesting conditions. The cost of equity-settled transactions are recognized as an expense with a corresponding increase in equity over the vesting period. The cumulative charge to profit or loss is calculated based on the grant date fair value of the award, the best estimate of the number of awards that are likely to vest and the expired portion of the vesting period. The amount recognized in profit or loss for the period is the cumulative amount calculated at each reporting date less amounts already recognized in previous periods. Market conditions are taken into consideration in determining fair value. Therefore any awards subject to market conditions are considered to vest irrespective of whether or not that market condition has been met, provided all other conditions are satisfied. If equity-settled awards are modified, as a minimum an expense is recognized as if the modification has not been made. An additional expense is recognized, over the remaining vesting period, for any modification that increases the total fair value of the share-based compensation benefit as at the date of modification. If the non-vesting condition is within the control of the Group or employee, the failure to satisfy the condition is treated as a cancellation. If the condition is not within the control of the Group or employee and is not satisfied during the vesting period, any remaining expense for the award is recognized over the remaining vesting period, unless the award is forfeited. If equity-settled awards are cancelled, it is treated as if it has vested on the date of cancellation, and any remaining expense is recognized immediately. If a new replacement award is substituted for the cancelled award, the cancelled and new award is treated as if they were a modification. The dilutive effect, if any, of outstanding options is reflected as additional share dilution in the computation of earnings per share.
Fair value measurement	(u) Fair value measurement When an asset or liability, financial or non-financial, is measured at fair value for recognition or disclosure purposes, the fair value is based on the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date; and assumes that the transaction will take place either: in the principal market; or in the absence of a principal market, in the most advantageous market. Fair value is measured using the assumptions that market participants would use when pricing the asset or liability, assuming they act in their economic best interests. For non-financial assets, the fair value measurement is based on its highest and best use. Valuation techniques that are appropriate in the circumstances and for which sufficient data is available to measure fair value, are used, maximising the use of relevant observable inputs and minimising the use of unobservable inputs.
Issued capital	(v) Issued capital Ordinary shares are classified as equity. Incremental costs directly attributable to the issue of new shares or options are shown in equity as a deduction, net of tax, from the proceeds. Costs related to an initial offering are expensed in the statement of profit or loss and other comprehensive income.
Earnings per share	(w) Earnings per share Basic earnings per share Basic earnings per share is calculated by dividing the profit attributable to the owners of Benitec Biopharma Limited, excluding any costs of servicing equity other than ordinary shares, by the weighted average number of ordinary shares outstanding during the financial year, adjusted for bonus elements in ordinary shares issued during the financial year. Diluted earnings per share Diluted earnings per share adjusts the figures used in the determination of basic earnings per share to take into account the after income tax effect of interest and other financing costs associated with dilutive potential ordinary shares and the weighted average number of shares assumed to have been issued for no consideration in relation to dilutive potential ordinary shares.
Goods and Services Tax ('GST') and other similar taxes	(x) Goods and Services Tax ('GST') and other similar taxes Revenues, expenses and assets are recognized net of the amount of associated GST, unless the GST incurred is not recoverable from the tax authority. In this case it is recognized as part of the cost of the acquisition of the asset or as part of the expense. Receivables and payables are stated inclusive of the amount of GST receivable or payable. The net amount of GST recoverable from, or payable to, the tax authority is included in other receivables or other payables in the statement of financial position. Cash flows are presented on a gross basis. The GST components of cash flows arising from investing or financing activities which are recoverable from, or payable to the tax authority, are presented as operating cash flows. Commitments and contingencies are disclosed net of the amount of GST recoverable from, or payable to, the tax authority.
Rounding of amounts	(y) Rounding of amounts The Parent entity has applied the relief available to it under ASIC Corporations (Rounding in Financial/Directors’ Reports) instrument 2016/191 and accordingly amounts in the financial statements and Directors Report have been rounded off to the nearest $1,000, or in certain cases, to the nearest dollars.

Significant Accounting Polici_3

Significant Accounting Policies (Tables)	12 Months Ended
	Jun. 30, 2018
Disclosure Of Significant Accounting Policies [Abstract]
Summary of Expected Useful Lives of Property, Plant and Equipment (Excluding Land)	Depreciation is calculated on a straight-line basis to write off the net cost of each item of property, plant and equipment (excluding land) over their expected useful lives as follows: Leasehold improvements period of the lease term Plant and equipment 3-7 years

Operating Segments (Tables)

Operating Segments (Tables)	12 Months Ended
	Jun. 30, 2018
Disclosure Of Operating Segments [Abstract]
Summary of Segment Revenues, Results or Assets by Geographical Location	Geographical Segments Geographical location Segment Revenues from External Customers Segment Results Carrying Amount of Segment Assets Jun 2018 Jun 2017 Jun 2018 Jun 2017 Jun 2018 Jun 2017 $’000 $’000 $’000 $’000 $’000 $’000 Australia 378 333 (11,733 ) (5,835 ) 19,639 21,580 United States of America — — 93 145 1,700 1,086 378 333 (11,640 ) (5,690 ) 21,339 22,666

Revenue and Other Income (Table

Revenue and Other Income (Tables)	12 Months Ended
	Jun. 30, 2018
Material Income And Expense [Abstract]
Summary of Revenue	2018 2017 2016 $’000 $’000 $’000 Licensing revenue and royalties 378 333 247 Interest 242 253 217 620 586 464
Summary of Other Income	Australian Government R&D grants 3,999 10,507 3,590 Foreign exchange unrealized gain 87 — — Other 1 — — 4,087 10,507 3,590

Expenses (Tables)

Expenses (Tables)	12 Months Ended
	Jun. 30, 2018
Material Income And Expense [Abstract]
Summary of Expenses	Loss before income tax includes the following specific expenses: Depreciation Leasehold improvements 25 53 205 Plant and equipment 169 164 85 Total depreciation 194 217 290 Research and development Project expenses 6,219 6,456 12,240 Other IP related expenses 671 469 1,047 Total research and development 6,890 6,925 13,287 Employee benefits expense Defined contribution superannuation expense 241 240 280 Employee benefits expense excluding superannuation 4,853 4,775 6,003 5,094 5,015 6,283 Rental expense relating to operating leases Minimum lease payments 384 376 265

Income Tax Benefit (Tables)

Income Tax Benefit (Tables)	12 Months Ended
	Jun. 30, 2018
Major Components Of Tax Expense Income [Abstract]
Summary of Income Tax Benefit and Reconciliation of Income Tax Benefit and Tax at the Statutory Rate	2018 2017 2016 $’000 $’000 $’000 Income tax benefit Current tax — — — Aggregate income tax benefit — — — Numerical reconciliation of income tax benefit and tax at the statutory rate Loss before income tax benefit (11,640 ) (5,690 ) (24,778 ) Tax at the statutory tax rate of 27.5% (2017:27.5%)(2016:30%) (3,201 ) (1,565 ) (7,433 ) Tax effect amounts which are not deductible/(taxable) in calculating taxable income: R&D expenses 2,605 2,676 4,151 R&D incentive income (1,124 ) (2,889 ) (1,090 ) Legal expenses 70 154 59 Share-based payments 119 106 524 Timing differences utilised not previously recognised (196 ) (506 ) (277 ) Write off prepayment — — 540 Impact of foreign exchange rate differences — 2 46 (1,727 ) (2,022 ) (3,480 ) Tax losses not brought to account 1,727 2,022 3,480 Income tax benefit — — —
Summary of Tax Losses for Which No Deferred Tax Asset has been Recognised	These tax losses are recognized only if the consolidated entity considers it is probable that future taxable amounts will be available to utilise those temporary differences and losses. Tax losses for which no deferred tax asset has been recognised - Australia - Tax losses not recognised 61,471 60,382 53,031 - Capital losses not recognised 1,272 1,272 1,272 - Other deferred tax assets not recognised 627 2,776 4,225 63,370 64,430 58,528 Potential tax benefit of tax assets not recognised at 27.5% (2017:27.5%) (2016:30%) 17,427 17,718 17,558 Tax losses for which no deferred tax asset has been recognised - US (Tacere) - Tax losses not recognised 846 955 1,137 Potential tax benefit of tax assets not recognised at 34% - US 233 324 387

Cash and Cash Equivalents (Tabl

Cash and Cash Equivalents (Tables)	12 Months Ended
	Jun. 30, 2018
Cash And Cash Equivalents [Abstract]
Summary of Cash and Cash Equivalents	2018 2017 $'000 $'000 Cash at bank 9,575 4,349 Cash on deposit 6,510 13,026 16,085 17,375

Other Financial Assets (Tables)

Other Financial Assets (Tables)	12 Months Ended
	Jun. 30, 2018
Disclosure Of Financial Assets [Abstract]
Summary of Other Financial Assets	2018 2017 $'000 $'000 Market value of listed shares 30 — Security Deposit 100 100 130 100

Trade and Other Receivables (Ta

Trade and Other Receivables (Tables)	12 Months Ended
	Jun. 30, 2018
Trade And Other Receivables [Abstract]
Summary of Trade and Other Receivables	2018 2017 $'000 $'000 Settlement Receivable — 109 R&D Grant Receivable 4,121 4,233 Other 134 64 4,255 4,406

Current Assets - Other (Tables)

Current Assets - Other (Tables)	12 Months Ended
	Jun. 30, 2018
Subclassifications Of Assets Liabilities And Equities [Abstract]
Summary of Current Assets - Other	2018 2017 $'000 $'000 Prepayments 425 281 425 281

Deposits Non-current (Tables)

Deposits Non-current (Tables)	12 Months Ended
	Jun. 30, 2018
Subclassifications Of Assets Liabilities And Equities [Abstract]
Summary of Deposits Non-current	2018 2017 $'000 $'000 Other 125 59 125 59

Property, Plant and Equipment (

Property, Plant and Equipment (Tables)	12 Months Ended
	Jun. 30, 2018
Disclosure Of Property Plant And Equipment [Abstract]
Summary of Property, Plant and Equipment	2018 2017 $'000 $'000 Leasehold improvements - at cost 79 79 Less: Accumulated depreciation (44 ) (19 ) 35 60 Plant and equipment - at cost 975 889 Less: Accumulated depreciation (691 ) (504 ) 284 385 319 445
Summary of Reconciliations of Property, Plant and Equipment	Reconciliations of the written down values at the beginning and end of the current and previous financial year are set out below: Leasehold Plant and improvement equipment Total $'000 $'000 $'000 Balance at June 30, 2016 44 462 506 Additions 74 97 171 Depreciation expense (53 ) (164 ) (217 ) FX loss (5 ) (10 ) (15 ) Balance at June 30, 2017 60 385 445 Additions — 86 86 Disposals — (27 ) (27 ) Depreciation expense (25 ) (169 ) (194 ) FX loss — 9 9 Balance at June 30, 2018 35 284 319

Trade and Other Payables (Table

Trade and Other Payables (Tables)	12 Months Ended
	Jun. 30, 2018
Trade And Other Payables [Abstract]
Summary of Trade and Other Payables	2018 2017 $'000 $'000 Trade creditors 580 174 Sundry creditors and accrued expenses 1,796 745 2,376 919

Provisions (Tables)

Provisions (Tables)	12 Months Ended
	Jun. 30, 2018
Provisions [Abstract]
Summary of Provisions	Employee Benefits 146 179 Provision for make good 25 27 171 206

Issued Capital (Tables)

Issued Capital (Tables)	12 Months Ended
	Jun. 30, 2018
Disclosure Of Classes Of Share Capital [Abstract]
Summary of Issued Capital	Issued capital 2018 2017 2018 2017 Shares Shares $'000 $'000 Ordinary shares - fully paid 257,029,426 205,142,734 164,087 155,580
Summary of Movements in Ordinary Share Capital	Movements in ordinary share capital Details Date Shares Issue price $'000 $ Balance June 30, 2017 205,142,734 155,580 Issue of shares Highbridge May 8, 2018 15,444,020 0.17 2,625 Issue of shares Nant Capital May 31, 2018 29,305,819 0.17 4,982 Issue of shares Entitlement offer June 4, 2018 7,136,853 0.17 1,213 Share issue transaction costs (313 ) Balance June 30, 2018 257,029,426 164,087 The weighted average number of shares on issue during the twelve months to June 30, 2018 was 210,454,829

Reserves (Tables)

Reserves (Tables)	12 Months Ended
	Jun. 30, 2018
Disclosure Of Reserves Within Equity [Abstract]
Summary of Reserves	2018 2017 $'000 $'000 Foreign currency reserve (1,348 ) (1,285 ) Share-based payments reserve 2,840 2,959 1,492 1,674
Summary of Movements in Each Class of Reserve	Movements in each class of reserve during the current and previous financial year are set out below: Foreign Share-based currency payments Total $'000 $'000 $'000 Balance at June 30, 2016 (1,319 ) 3,884 2,565 Foreign currency translation 34 — 34 Share-based payments — (925 ) (925 ) Balance at June 30, 2017 (1,285 ) 2,959 1,674 Foreign currency translation (63 ) — (63 ) Share-based payments — (119 ) (119 ) Balance at June 30, 2018 (1,348 ) 2,840 1,492

Accumulated Losses (Tables)

Accumulated Losses (Tables)	12 Months Ended
	Jun. 30, 2018
Retained Earnings [Abstract]
Summary of Accumulated Losses	2018 2017 $'000 $'000 Accumulated losses at the beginning of the financial year (135,748 ) (131,369 ) Loss after income tax benefit for the year (11,640 ) (5,690 ) Transfer from share-based payment reserve for expired options 553 1,311 Accumulated losses at the end of the financial year (146,835 ) (135,748 )

Financial Instruments (Tables)

Financial Instruments (Tables)	12 Months Ended
	Jun. 30, 2018
Disclosure Of Financial Instruments [Line Items]
Summary of Financial Instruments	2018 2017 $'000 $'000 Financial Assets Cash and cash equivalents 16,085 17,375 Trade and other receivables 4,255 4,406 Total Financial Assets 20,340 21,781 Financial Liabilities Trade and other payables 2,376 919 Total Financial Liabilities 2,376 919
Summary of Group's Remaining Contractual Maturity for its Financial Instrument Liabilities	The following tables detail the Group's remaining contractual maturity for its financial instrument liabilities. The tables have been drawn up based on the undiscounted cash flows of financial liabilities based on the earliest date on which the financial liabilities are required to be paid. Weighted average interest rate 1 year or less Between 1 and 2 years Between 2 and 5 years Over 5 years Remaining contractual maturities 2018 % $'000 $'000 $'000 $'000 $'000 Non-derivatives Non-interest bearing Trade payables -% 580 — — — 580 Other payables -% 1,796 — — — 1,796 Total non-derivatives 2,376 — — — 2,376 2017 % $'000 $'000 $'000 $'000 $'000 Non-derivatives Non-interest bearing Trade payables -% 174 — — — 174 Other payables -% 745 — — — 745 Total non-derivatives 919 — — — 919 2016 % $'000 $'000 $'000 $'000 $'000 Non-derivatives Non-interest bearing Trade payables -% 538 — — — 538 Other payables -% 295 — — — 295 Total non-derivatives 833 — — — 833
Interest rate risk [member]
Disclosure Of Financial Instruments [Line Items]
Summary of Variable Rate Cash and Cash Equivalents Outstanding	As at the reporting date, the Group had the following variable rate cash and cash equivalents outstanding: 2018 2017 Weighted average interest rate Balance Weighted average interest rate Balance % $'000 % $'000 Cash and cash equivalents 2 % 16,085 1 % 17,375 Net exposure to cash flow interest rate risk 16,085 17,375

Remuneration of Auditors (Table

Remuneration of Auditors (Tables)	12 Months Ended
	Jun. 30, 2018
Auditors Remuneration [Abstract]
Summary of Remuneration of Auditors	During the financial year the following fees were paid or payable for services provided by Grant Thornton Audit Pty Ltd, the auditor of the Company: 2018 2017 Audit services - Grant Thornton Audit Pty Ltd $ $ Audit or review of the financial statements 240,806 241,933 Other audit services - F1 consent 17,990 20,800 - F3 consent 6,660 9,561 Other services - Grant Thornton Audit Pty Ltd Tax compliance services 42,617 23,150 42,617 23,150 308,073 295,444

Commitments (Tables)

Commitments (Tables)	12 Months Ended
	Jun. 30, 2018
Disclosure Of Finance Lease And Operating Lease By Lessee [Abstract]
Summary of Lease Commitments - Operating	2018 2017 2016 $'000 $'000 $'000 Lease commitments - operating Committed at the reporting date but not recognised as liabilities, payable: Within one year 219 169 126 One to five years 293 89 98 512 258 224

Related Party Transactions (Tab

Related Party Transactions (Tables)	12 Months Ended
	Jun. 30, 2018
Disclosure Of Transactions Between Related Parties [Abstract]
Summary of Compensation of Key Management Personnel and Transactions with Related Parties	The aggregate compensation made to directors and other members of key management personnel of the Group is set out below: 2018 2017 2016 $ $ $ Short-term employee benefits 1,843,334 1,539,777 2,048,543 Post-employment benefits 89,780 76,623 55,630 Long-term benefits — 32,537 13,209 Share-based payments 257,001 418,986 1,011,851 2,190,115 2,067,923 3,129,233 The following transactions occurred with related parties: Payment for other expenses: Legal services paid / payable to Francis Abourizk Lightowlers, a law firm in which Mr Peter Francis is a partner and has a beneficial interest. 8,212 191,050 116,540 Payment for rent at Francis Abourizk Lightowlers law firm which Mr Peter Francis is a partner and has a beneficial interest — — 11,102 Consultancy fees for executive duties paid/payable to NewStar Ventures Ltd, a corporation in which Dr John Chiplin is a director and has a beneficial interest. — 32,133 165,983 Annabel West, the wife of Greg West, our former Chief Executive Officer, was employed as a part-time clerical and administrative assistant. 42,278 36,248 47,722

Parent Entity Information (Tabl

Parent Entity Information (Tables)	12 Months Ended
	Jun. 30, 2018
Disclosure Of Parent Entity Information [Abstract]
Summary of Parent Entity Information	Set out below is the supplementary information about the parent entity. 2018 2017 $'000 $'000 Statement of profit or loss and other comprehensive income Loss after income tax (13,566 ) (5,835 ) Total comprehensive income (13,566 ) (5,835 ) Statement of financial position Total current assets 19,461 21,421 Total assets 19,639 22,868 Total current liabilities 2,351 969 Total liabilities 2,399 1,004 Equity Issued capital 164,087 155,580 Share-based payments reserve 2,840 2,959 Accumulated losses (149,687 ) (136,675 ) Total equity 17,240 21,864

Interests in Subsidiaries (Tabl

Interests in Subsidiaries (Tables)	12 Months Ended
	Jun. 30, 2018
Disclosure Of Significant Investments In Subsidiaries [Abstract]
Summary of Interests in Subsidiaries	The consolidated financial statements incorporate the assets, liabilities and results of the following subsidiaries in accordance with the accounting policy described in note 1: Principal place of business / 2018 2017 2016 Name Country of incorporation % % % Benitec Limited United Kingdom 100% 100% 100% Benitec Australia Limited (subsidiary of Benitec Limited) Australia 100% 100% 100% Benitec, Inc. USA 100% 100% 100% Benitec LLC (subsidiary of Benitec Inc) USA 100% 100% 100% RNAi Therapeutics, Inc. USA 100% 100% 100% Tacere Therapeutics, Inc.* USA 100% 100% 100% * Note Tacere year end is 31 December which was the year end date when the Company was acquired.

Reconciliation of Loss after _2

Reconciliation of Loss after Income Tax to Net Cash Used in Operating Activities (Tables)	12 Months Ended
	Jun. 30, 2018
Reconciliation Of Loss After Income Tax To Net Cash Used In Operating Activities [Abstract]
Summary of Reconciliation of Loss after Income Tax to Net Cash Used in Operating Activities	2018 $'000 2017 $'000 2016 $'000 Loss after income tax benefit for the year (11,640 ) (5,690 ) (24,778 ) Adjustments for: Loss on disposal of fixed assets 1 6 — Depreciation and amortisation 194 217 290 Share-based payments 434 386 1,746 Net unrealised Foreign exchange (82 ) 242 506 Issue of ordinary shares to Biomics — — 500 Impairment of prepayment — — 1,800 Change in operating assets and liabilities: Increase in trade and other receivables 72 814 (854 ) (Decrease) in other current assets (121 ) (182 ) 1,178 Increase in trade and other payables 1,259 114 (623 ) (Decrease) in R&D grant receivable 112 (4,233 ) — (Decrease) in employee benefits (23 ) (3 ) 27 Increase in provision — 25 — Net cash used in operating activities (9,794 ) (8,304 ) (20,208 )

Earnings Per Share (Tables)

Earnings Per Share (Tables)	12 Months Ended
	Jun. 30, 2018
Earnings Per Share [Abstract]
Summary of Earnings Per Share	Loss after income tax attributable to the owners of Benitec Biopharma Limited (11,640 ) (5,690 ) (24,778 ) Number Number Number Weighted average number of ordinary shares used in calculating basic earnings per share 210,454,829 175,433,909 142,312,486 Weighted average number of ordinary shares used in calculating diluted earnings per share 210,454,829 175,433,909 142,312,486 Cents Cents Cents Basic (loss) per share (5.53 ) (3.24 ) (17.41 ) Diluted (loss) per share (5.53 ) (3.24 ) (17.41 )

Share-based Payments (Tables)

Share-based Payments (Tables)	12 Months Ended
	Jun. 30, 2018
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Abstract]
Summary of Number and Weighted Average Exercise Price of Share Options	The following table shows the number and weighted average exercise price (WAEP) of share options issued under the ESOP: 2018 2018 2017 2017 2016 2016 Number WAEP Number WAEP Number WAEP $ $ $ Outstanding at the beginning of the year 9,724,000 0.832 12,220,000 1.079 12,500,000 1.234 Granted during the year 19,950,000 0.218 2,200,000 0.166 6,720,000 0.770 Exercised during the year — — — — — — Lapsed or forfeited during the year (5,196,668 ) 0.426 (4,696,000 ) 1.164 (7,000,000 ) 1.060 Outstanding at the end of the year 24,477,332 0.416 9,724,000 0.832 12,220,000 1.079 Options exercisable at the end of the year 6,527,333 6,497,333 8,292,000
Summary of Details of ESOP Share Options Outstanding	Details of ESOP share options outstanding as at end of year: 2018 2017 2016 Exercise Number Number Number Grant date Expiry date price Under option Under option Under option September 26, 2011* September 26, 2016 $ 1.250 — — 2,800,000 November 17, 2012 ** November 17, 2017 $ 1.250 — 400,000 600,000 February 7, 2012** February 7, 2017 $ 1.250 — — 156,000 November 6, 2012** November 6, 2017 $ 1.250 — — 400,000 November 10, 2013 * May 18 2018 $ 0.620 — 400,000 400,000 August 22, 2013 ** August 22 2018 $ 1.250 480,000 480,000 480,000 May 15, 2014 ** May 15, 2019 $ 1.500 90,000 180,000 180,000 December 17, 2014 ** December 17, 2019 $ 1.250 2,334,000 2,334,000 2,634,000 May 6, 2015 ** May 6, 2020 $ 1.250 650,000 650,000 650,000 November 12, 2015* November 12, 2020 $ 0.770 2,240,000 3,080,000 3,920,000 August 9, 2016** August 9, 2021 $ 0.167 1,466,666 2,200,000 — July 17, 2017** July 17, 2022 $ 0.196 6,566,666 — — April 11, 2018** April 11, 2023 $ 0.298 650,000 — — June 26, 2018** June 26, 2023 $ 0.228 10,000,000 — — 24,477,332 9,724,000 12,220,000 * Non-Executive Directors options ** ESOP options
Summary of Valuation Model Inputs used to Determine the Fair Value at the Grant Date	For the options granted during the year, the valuation model inputs used to determine the fair value at the grant date are as follows: Grant date Expiry date Share price Exercise Expected * Dividend Risk-free Fair value at grant date price volatility yield interest rate at grant date 17/07/2017 17/07/2022 $ 0.130 $ 0.196 100.01 % —% 2.370 % $ 0.091 11/04/2018 11/04/2023 $ 0.200 $ 0.298 101.43 % —% 2.373 % $ 0.141 26/06/2018 26/06/2023 $ 0.145 $ 0.228 100.31 % —% 2.303 % $ 0.100 * expected volatility was determined with reference to the Benitec share price based on historical volatility

Significant Accounting Polici_4

Significant Accounting Policies - Additional Information (Detail) $ in Thousands, $ in Millions	Jul. 09, 2018AUD ($)	Jul. 09, 2018USD ($)	Jun. 30, 2018AUD ($)	Jun. 30, 2017AUD ($)	Jun. 30, 2016AUD ($)	Jun. 30, 2015AUD ($)
Disclosure of significant accounting policies [line items]
Net loss for the year			$ 11,640	$ 5,690	$ 24,778
Cash and cash equivalents balance			$ 16,085	$ 17,375	$ 18,230	$ 21,787
Percentage of eligible research and development expenditures in which the government provides a cash refund			43.50%	43.50%
Tacere Therapeutics, Inc. [Member]
Disclosure of significant accounting policies [line items]
Ownership percentage in subsidiary			100.00%	100.00%	100.00%
Axovant Sciences [Member] | License Agreement and Fully Funded Collaboration [Member]
Disclosure of significant accounting policies [line items]
Upfront cash payment received	$ 13,500	$ 10

Significant Accounting Polici_5

Significant Accounting Policies - Summary of Expected Useful Lives of Property, Plant and Equipment (Excluding Land) (Detail)	12 Months Ended
	Jun. 30, 2018
Leasehold Improvements [Member]
Disclosure of Detailed Information About Property, Plant and Equipment [Line Items]
Description of expected useful lives of property, plant and equipment	period of the lease term
Plant and Equipment [Member]
Disclosure of Detailed Information About Property, Plant and Equipment [Line Items]
Description of expected useful lives of property, plant and equipment	3-7 years

Critical Accounting Judgement_2

Critical Accounting Judgements, Estimates and Assumptions - Additional Information (Detail) - AUD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2016
Disclosure Of Changes In Accounting Estimates [Abstract]
Grant Income includes an estimate of Research and Development grant receivable	$ 3,999	$ 10,507	$ 3,590

Operating Segments - Additional

Operating Segments - Additional Information (Detail)	12 Months Ended
	Jun. 30, 2018Segment
Disclosure Of Operating Segments [Abstract]
Number of operating segments	1

Operating Segments - Summary of

Operating Segments - Summary of Segment Revenues, Results or Assets by Geographical Location (Detail) - AUD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2016
Disclosure Of Geographical Areas [Line Items]
Segment Revenues from External Customers	$ 378	$ 333	$ 247
Segment Results	(11,640)	(5,690)	$ (24,778)
Carrying Amount of Segment Assets	21,339	22,666
Australia [Member]
Disclosure Of Geographical Areas [Line Items]
Segment Revenues from External Customers	378	333
Segment Results	(11,733)	(5,835)
Carrying Amount of Segment Assets	19,639	21,580
United States of America [Member]
Disclosure Of Geographical Areas [Line Items]
Segment Results	93	145
Carrying Amount of Segment Assets	$ 1,700	$ 1,086

Revenue and Other Income - Summ

Revenue and Other Income - Summary of Revenue (Detail) - AUD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2016
Revenue [Abstract]
Licensing revenue and royalties	$ 378	$ 333	$ 247
Interest	242	253	217
Revenue	$ 620	$ 586	$ 464

Revenue and Other Income - Su_2

Revenue and Other Income - Summary of Other Income (Detail) - AUD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2016
Material Income And Expense [Abstract]
Australian Government R&D grants	$ 3,999	$ 10,507	$ 3,590
Foreign exchange unrealized gain	87
Other	1
Other income	$ 4,087	$ 10,507	$ 3,590

Expenses - Summary of Expenses

Expenses - Summary of Expenses (Detail) - AUD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2016
Depreciation
Total depreciation	$ 194	$ 217	$ 290
Research and development
Project expenses	6,219	6,456	12,240
Other IP related expenses	671	469	1,047
Total research and development	6,890	6,925	13,287
Employee benefits expense
Defined contribution superannuation expense	241	240	280
Employee benefits expense excluding superannuation	4,853	4,775	6,003
Total employee benefits expense	5,094	5,015	6,283
Rental expense relating to operating leases
Minimum lease payments	384	376	265
Leasehold Improvements [Member]
Depreciation
Total depreciation	25	53	205
Plant and Equipment [Member]
Depreciation
Total depreciation	$ 169	$ 164	$ 85

Income Tax Benefit - Summary of

Income Tax Benefit - Summary of Income Tax Benefit and Reconciliation of Income Tax Benefit and Tax at the Statutory Rate (Detail) - AUD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2016
Income tax benefit
Income tax benefit	$ 0	$ 0	$ 0
Numerical reconciliation of income tax benefit and tax at the statutory rate
Loss before income tax benefit	(11,640)	(5,690)	(24,778)
Tax at the statutory tax rate of 27.5% (2017:27.5%)(2016:30%)	(3,201)	(1,565)	(7,433)
Tax effect amounts which are not deductible/(taxable) in calculating taxable income:
R&D expenses	2,605	2,676	4,151
R&D incentive income	(1,124)	(2,889)	(1,090)
Legal expenses	70	154	59
Share-based payments	119	106	524
Timing differences utilised not previously recognised	(196)	(506)	(277)
Write off prepayment			540
Impact of foreign exchange rate differences		(2)	(46)
Tax effect of amounts which are not deductible/(taxable)	(1,727)	(2,022)	(3,480)
Tax losses not brought to account	1,727	2,022	3,480
Income tax benefit	$ 0	$ 0	$ 0

Income Tax Benefit - Summary _2

Income Tax Benefit - Summary of Income Tax Benefit and Reconciliation of Income Tax Benefit and Tax at the Statutory Rate (Parenthetical) (Detail)	12 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2016
Australia [Member]
Disclosure Of Temporary Difference Unused Tax Losses And Unused Tax Credits [Line Items]
Tax at the statutory tax percentage	27.50%	27.50%	30.00%

Income Tax Benefit - Summary _3

Income Tax Benefit - Summary of Tax Losses for Which No Deferred Tax Asset has been Recognised (Detail) - AUD ($)	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2016
Australia [Member]
Disclosure Of Temporary Difference Unused Tax Losses And Unused Tax Credits [Line Items]
Tax losses not recognised	$ 61,471	$ 60,382	$ 53,031
Capital losses not recognised	1,272	1,272	1,272
Other deferred tax assets not recognised	627	2,776	4,225
Tax losses for which no deferred tax asset has been recognised	63,370	64,430	58,528
Potential tax benefit of tax assets not recognised	17,427	17,718	17,558
United States of America [Member]
Disclosure Of Temporary Difference Unused Tax Losses And Unused Tax Credits [Line Items]
Tax losses not recognised	846	955	1,137
Potential tax benefit of tax assets not recognised	$ 233	$ 324	$ 387

Income Tax Benefit - Summary _4

Income Tax Benefit - Summary of Tax Losses for Which No Deferred Tax Asset has been Recognised (Parenthetical) (Detail)	12 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2016
Australia [Member]
Disclosure Of Temporary Difference Unused Tax Losses And Unused Tax Credits [Line Items]
Tax at the statutory tax percentage	27.50%	27.50%	30.00%
United States of America [Member]
Disclosure Of Temporary Difference Unused Tax Losses And Unused Tax Credits [Line Items]
Tax at the statutory tax percentage	34.00%

Cash and Cash Equivalents - Sum

Cash and Cash Equivalents - Summary of Cash and Cash Equivalents (Detail) - AUD ($) $ in Thousands	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2015
Cash And Cash Equivalents [Abstract]
Cash at bank	$ 9,575	$ 4,349
Cash on deposit	6,510	13,026
Cash and cash equivalents	$ 16,085	$ 17,375	$ 18,230	$ 21,787

Other Financial Assets - Summar

Other Financial Assets - Summary of Other Financial Assets (Detail) - AUD ($) $ in Thousands	Jun. 30, 2018	Jun. 30, 2017
Categories Of Current Financial Assets [Abstract]
Market value of listed shares	$ 30
Security deposit	100	$ 100
Total other financial assets	$ 130	$ 100

Trade and Other Receivables - S

Trade and Other Receivables - Summary of Trade and Other Receivables (Detail) - AUD ($) $ in Thousands	Jun. 30, 2018	Jun. 30, 2017
Trade And Other Current Receivables [Abstract]
Settlement Receivable		$ 109
R&D Grant Receivable	$ 4,121	4,233
Other	134	64
Total trade and other receivables	$ 4,255	$ 4,406

Current Assets - Other - Summar

Current Assets - Other - Summary of Current Assets - Other (Detail) - AUD ($) $ in Thousands	Jun. 30, 2018	Jun. 30, 2017
Miscellaneous Current Assets [Abstract]
Prepayments	$ 425	$ 281
Total Current Assets Other	$ 425	$ 281

Deposits Non - current - Summar

Deposits Non - current - Summary of Deposits Non-current (Details) - AUD ($) $ in Thousands	Jun. 30, 2018	Jun. 30, 2017
Subclassifications Of Assets Liabilities And Equities [Abstract]
Other	$ 125	$ 59
Deposits	$ 125	$ 59

Property, Plant and Equipment -

Property, Plant and Equipment - Summary of Property, Plant and Equipment (Detail) - AUD ($) $ in Thousands	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2016
Disclosure of Detailed Information About Property, Plant and Equipment [Line Items]
Plant and equipment	$ 319	$ 445	$ 506
Leasehold Improvements [Member]
Disclosure of Detailed Information About Property, Plant and Equipment [Line Items]
Plant and equipment	35	60	44
Leasehold Improvements [Member] | At Cost [Member]
Disclosure of Detailed Information About Property, Plant and Equipment [Line Items]
Plant and equipment	79	79
Leasehold Improvements [Member] | Accumulated Depreciation [Member]
Disclosure of Detailed Information About Property, Plant and Equipment [Line Items]
Plant and equipment	(44)	(19)
Plant and Equipment [Member]
Disclosure of Detailed Information About Property, Plant and Equipment [Line Items]
Plant and equipment	284	385	$ 462
Plant and Equipment [Member] | At Cost [Member]
Disclosure of Detailed Information About Property, Plant and Equipment [Line Items]
Plant and equipment	975	889
Plant and Equipment [Member] | Accumulated Depreciation [Member]
Disclosure of Detailed Information About Property, Plant and Equipment [Line Items]
Plant and equipment	$ (691)	$ (504)

Property, Plant and Equipment_2

Property, Plant and Equipment - Summary of Reconciliations of Property, Plant and Equipment (Detail) - AUD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2018	Jun. 30, 2017
Disclosure of Detailed Information About Property, Plant and Equipment [Line Items]
Beginning balance	$ 445	$ 506
Additions	86	171
Disposals	(27)
Depreciation expense	(194)	(217)
FX loss	9	(15)
Ending balance	319	445
Leasehold Improvements [Member]
Disclosure of Detailed Information About Property, Plant and Equipment [Line Items]
Beginning balance	60	44
Additions		74
Depreciation expense	(25)	(53)
FX loss		(5)
Ending balance	35	60
Plant and Equipment [Member]
Disclosure of Detailed Information About Property, Plant and Equipment [Line Items]
Beginning balance	385	462
Additions	86	97
Disposals	(27)
Depreciation expense	(169)	(164)
FX loss	9	(10)
Ending balance	$ 284	$ 385

Trade and Other Payables - Summ

Trade and Other Payables - Summary of Trade and Other Payables (Detail) - AUD ($) $ in Thousands	Jun. 30, 2018	Jun. 30, 2017
Trade And Other Payables [Abstract]
Trade creditors	$ 580	$ 174
Sundry creditors and accrued expenses	1,796	745
Total trade and other payables	$ 2,376	$ 919

Provisions - Summary of Provisi

Provisions - Summary of Provisions (Detail) - AUD ($) $ in Thousands	Jun. 30, 2018	Jun. 30, 2017
Provisions [Abstract]
Employee Benefits	$ 146	$ 179
Provision for make good	25	27
Total provisions	$ 171	$ 206

Issued Capital - Summary of Iss

Issued Capital - Summary of Issued Capital (Detail) - AUD ($) $ in Thousands	Jun. 30, 2018	Jun. 30, 2017
Disclosure Of Classes Of Share Capital [Abstract]
Ordinary shares - fully paid, shares	257,029,426	205,142,734
Ordinary shares - fully paid	$ 164,087	$ 155,580

Issued Capital - Summary of Mov

Issued Capital - Summary of Movements in Ordinary Share Capital (Detail) - AUD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2016
Disclosure Of Classes Of Share Capital [Line Items]
Beginning balance, shares	205,142,734
Ending balance, shares	257,029,426	205,142,734
The weighted average number of shares on issue during the twelve months to June 30, 2018 was	210,454,829	175,433,909	142,312,486
Beginning balance, value	$ 155,580
Contributions of equity, net of transaction costs	8,507	$ 7,939	$ 18,010
IPO and share issue transaction cost	(313)	(133)	$ (1,952)
Ending balance, value	$ 164,087	$ 155,580
Issue of Shares Highbridge [Member]
Disclosure Of Classes Of Share Capital [Line Items]
Date	May 8, 2018
Issue price	$ 0.17
Issue of shares	15,444,020
Contributions of equity, net of transaction costs	$ 2,625
Issue of Shares Nant Capital [Member]
Disclosure Of Classes Of Share Capital [Line Items]
Date	May 31, 2018
Issue price	$ 0.17
Issue of shares	29,305,819
Contributions of equity, net of transaction costs	$ 4,982
Issue of Shares Entitlement Offer [Member]
Disclosure Of Classes Of Share Capital [Line Items]
Date	Jun. 4, 2018
Issue price	$ 0.17
Issue of shares	7,136,853
Contributions of equity, net of transaction costs	$ 1,213

Issued Capital - Additional Inf

Issued Capital - Additional Information (Detail)	Jun. 30, 2018Vote$ / sharesshares
Disclosure Of Classes Of Share Capital [Line Items]
Number of ordinary shares represented by 1 ADR | shares	20
Ordinary shares [member]
Disclosure Of Classes Of Share Capital [Line Items]
Par value per share | $ / shares
Number of vote per share | Vote	1

Reserves - Summary of Reserves

Reserves - Summary of Reserves (Detail) - AUD ($) $ in Thousands	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2016
Disclosure Of Reserves Within Equity [Abstract]
Foreign currency reserve	$ (1,348)	$ (1,285)
Share-based payments reserve	2,840	2,959
Reserves	$ 1,492	$ 1,674	$ 2,565

Reserves - Summary of Movements

Reserves - Summary of Movements in Each Class of Reserve (Detail) - AUD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2016
Disclosure Of Reserves Within Equity [Line Items]
Beginning balance	$ 1,674	$ 2,565
Foreign currency translation loss	(63)	34	$ (19)
Share-based payments	(119)	(925)
Ending balance	1,492	1,674	2,565
Foreign Currency Reserve [Member]
Disclosure Of Reserves Within Equity [Line Items]
Beginning balance	(1,285)	(1,319)
Foreign currency translation loss	(63)	34
Ending balance	(1,348)	(1,285)	(1,319)
Share-based Payments Reserve [Member]
Disclosure Of Reserves Within Equity [Line Items]
Beginning balance	2,959	3,884
Share-based payments	(119)	(925)
Ending balance	$ 2,840	$ 2,959	$ 3,884

Accumulated Losses - Summary of

Accumulated Losses - Summary of Accumulated Losses (Detail) - AUD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2016
Beginning balance	$ 21,506	$ 18,837	$ 23,878
Loss after income tax benefit for the year	(11,640)	(5,690)	(24,778)
Ending balance	18,744	21,506	18,837
Accumulated Losses [Member]
Beginning balance	(135,748)	(131,369)	(107,791)
Loss after income tax benefit for the year	(11,640)	(5,690)	(24,778)
Transfer from share-based payment reserve for expired options	553	1,311	1,200
Ending balance	$ (146,835)	$ (135,748)	$ (131,369)

Dividends - Additional Informat

Dividends - Additional Information (Detail) - AUD ($)	12 Months Ended
	Jun. 30, 2018	Jun. 30, 2017
Disclosure Of Dividends [Abstract]
Dividends paid	$ 0	$ 0

Financial Instruments - Summary

Financial Instruments - Summary of Financial Instruments (Detail) - AUD ($) $ in Thousands	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2015
Financial Assets
Cash and cash equivalents	$ 16,085	$ 17,375	$ 18,230	$ 21,787
Trade and other receivables	4,255	4,406
Total Financial Assets	20,340	21,781
Financial Liabilities
Trade and other payables	2,376	919
Total Financial Liabilities	$ 2,376	$ 919

Financial Instruments - Additio

Financial Instruments - Additional Information (Detail) - AUD ($)	12 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2015
Disclosure Of Risk Management Strategy Related To Hedge Accounting [Line Items]
Cash or cash equivalents	$ 16,085,000	$ 17,375,000	$ 18,230,000	$ 21,787,000
Trade payables and accruals	2,376,000	$ 919,000
Currency risk [member] | United States of America, Dollars
Disclosure Of Risk Management Strategy Related To Hedge Accounting [Line Items]
Cash or cash equivalents	7,536,000
Trade payables and accruals	1,630,000
Net USD exposure	5,907,000
Potential movement in exchange rate	0.01
Increase (decrease) in profit loss and net assets due to potential movement in exchange rate	$ 82,000

Financial Instruments - Summa_2

Financial Instruments - Summary of Variable Rate Cash and Cash Equivalents Outstanding (Detail) - AUD ($) $ in Thousands	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2015
Disclosure Of Nature And Extent Of Risks Arising From Financial Instruments [Line Items]
Cash and cash equivalents	$ 16,085	$ 17,375	$ 18,230	$ 21,787
Interest rate risk [member]
Disclosure Of Nature And Extent Of Risks Arising From Financial Instruments [Line Items]
Weighted average interest rate	2.00%	1.00%
Cash and cash equivalents	$ 16,085	$ 17,375
Net exposure to cash flow interest rate risk	$ 16,085	$ 17,375

Financial Instruments - Summa_3

Financial Instruments - Summary of Group's Remaining Contractual Maturity for its Financial Instrument Liabilities (Detail) - AUD ($) $ in Thousands	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2016
Disclosure Of Maturity Analysis For Nonderivative Financial Liabilities [Line Items]
Trade payables	$ 580	$ 174	$ 538
Other payables	1,796	745	295
Total non-derivatives	2,376	919	833
1 Year or Less [Member]
Disclosure Of Maturity Analysis For Nonderivative Financial Liabilities [Line Items]
Trade payables	580	174	538
Other payables	1,796	745	295
Total non-derivatives	$ 2,376	$ 919	$ 833

Remuneration of Auditors - Summ

Remuneration of Auditors - Summary of Remuneration of Auditors (Detail) - AUD ($)	12 Months Ended
	Jun. 30, 2018	Jun. 30, 2017
Auditors Remuneration [Line Items]
Audit or review of the financial statements	$ 240,806	$ 241,933
Tax compliance services	42,617	23,150
Other services	42,617	23,150
Remuneration of auditors	308,073	295,444
F1 Consent [Member]
Auditors Remuneration [Line Items]
Other audit services	17,990	20,800
F3 Consent [Member]
Auditors Remuneration [Line Items]
Other audit services	$ 6,660	$ 9,561

Commitments - Summary of Lease

Commitments - Summary of Lease Commitments - Operating (Detail) - AUD ($) $ in Thousands	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2016
Disclosure Of Finance Lease And Operating Lease By Lessee [Line Items]
Lease commitments - operating	$ 512	$ 258	$ 224
Within One Year [Member]
Disclosure Of Finance Lease And Operating Lease By Lessee [Line Items]
Lease commitments - operating	219	169	126
One to Five Years [Member]
Disclosure Of Finance Lease And Operating Lease By Lessee [Line Items]
Lease commitments - operating	$ 293	$ 89	$ 98

Commitments - Additional Inform

Commitments - Additional Information (Detail)	12 Months Ended
	Jun. 30, 2018
Disclosure Of Finance Lease And Operating Lease By Lessee [Abstract]
Expiring period of operating lease commitments	3 years

Contingent Liabilities - Additi

Contingent Liabilities - Additional Information (Detail) - Jun. 30, 2018 - Milestone Payment Contingent Liability [Member] $ in Thousands	AUD ($)	USD ($)	GBP (£)
NantWorks LLC [Member]
Disclosure of contingent liabilities [Line Items]
Amount of milestone payment	$ 405,000	$ 300
Oxford Expression Technologies (OET) [Member]
Disclosure of contingent liabilities [Line Items]
Amount of milestone payment	$ 53,543		£ 30,000

Related Party Transactions - Su

Related Party Transactions - Summary of Compensation of Key Management Personnel and Transactions with Related Parties (Detail) - AUD ($)	12 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2016
Disclosure Of Transactions Between Related Parties [Line Items]
Short-term employee benefits	$ 1,843,334	$ 1,539,777	$ 2,048,543
Post-employment benefits	89,780	76,623	55,630
Long-term benefits		32,537	13,209
Share-based payments	257,001	418,986	1,011,851
Key management personnel compensation	2,190,115	2,067,923	3,129,233
Francis Abourizk Lightowlers [Member]
Disclosure Of Transactions Between Related Parties [Line Items]
Legal services paid / payable to Francis Abourizk Lightowlers, a law firm in which Mr Peter Francis is a partner and has a beneficial interest.	8,212	191,050	116,540
Payment for rent at Francis Abourizk Lightowlers law firm which Mr Peter Francis is a partner and has a beneficial interest			11,102
NewStar Ventures Ltd [Member]
Disclosure Of Transactions Between Related Parties [Line Items]
Consultancy fees for executive duties paid/payable to NewStar Ventures Ltd, a corporation in which Dr John Chiplin is a director and has a beneficial interest.		32,133	165,983
Annabel West [Member]
Disclosure Of Transactions Between Related Parties [Line Items]
Annabel West, the wife of Greg West, our former Chief Executive Officer, was employed as a part-time clerical and administrative assistant.	$ 42,278	$ 36,248	$ 47,722

Related Party Transactions - Ad

Related Party Transactions - Additional Information (Detail) - AUD ($)	Jun. 30, 2018	Jun. 30, 2017
Disclosure Of Transactions Between Related Parties [Abstract]
Trade receivable from related party	$ 0	$ 0
Trade payments to related party	0	0
Loans to related party	0	0
Loans from related party	$ 0	$ 0

Parent Entity Information - Sum

Parent Entity Information - Summary of Parent Entity Information (Detail) - AUD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2015
Statement of profit or loss and other comprehensive income
Loss after income tax benefit for the year	$ (11,640)	$ (5,690)	$ (24,778)
Total comprehensive income	(11,703)	(5,656)	(24,797)
Statement of financial position
Total current assets	20,895	22,162
Total assets	21,339	22,666
Total current liabilities	2,547	1,125
Total liabilities	2,595	1,160
EQUITY
Issued capital	164,087	155,580
Share-based payments reserve	2,840	2,959
Accumulated losses	(146,835)	(135,748)
TOTAL EQUITY	18,744	21,506	$ 18,837	$ 23,878
Parent [Member]
Statement of profit or loss and other comprehensive income
Loss after income tax benefit for the year	(13,566)	(5,835)
Total comprehensive income	(13,566)	(5,835)
Statement of financial position
Total current assets	19,461	21,421
Total assets	19,639	22,868
Total current liabilities	2,351	969
Total liabilities	2,399	1,004
EQUITY
Issued capital	164,087	155,580
Share-based payments reserve	2,840	2,959
Accumulated losses	(149,687)	(136,675)
TOTAL EQUITY	$ 17,240	$ 21,864

Parent Entity Information - Add

Parent Entity Information - Additional Information (Detail) - Parent [Member] - AUD ($)	12 Months Ended
	Jun. 30, 2018	Jun. 30, 2017
Disclosure Of Transactions Between Related Parties [Line Items]
Guarantees in relation to the debts of its subsidiaries	$ 0	$ 0
Contingent liabilities	0	0
Capital commitments for property, plant and equipment	$ 0	$ 0

Interests in Subsidiaries - Sum

Interests in Subsidiaries - Summary of Interests in Subsidiaries (Detail)	12 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2016
Benitec Limited [Member]
Disclosure Of Significant Investments In Subsidiaries [Line Items]
Name of subsidiary	Benitec Limited
Principal place of business	United Kingdom
Country of incorporation	United Kingdom
Ownership percentage in subsidiary	100.00%	100.00%	100.00%
Benitec Australia Limited [Member]
Disclosure Of Significant Investments In Subsidiaries [Line Items]
Name of subsidiary	Benitec Australia Limited (subsidiary of Benitec Limited)
Principal place of business	Australia
Country of incorporation	Australia
Ownership percentage in subsidiary	100.00%	100.00%	100.00%
Benitec, Inc. [Member]
Disclosure Of Significant Investments In Subsidiaries [Line Items]
Name of subsidiary	Benitec, Inc.
Principal place of business	USA
Country of incorporation	USA
Ownership percentage in subsidiary	100.00%	100.00%	100.00%
Benitec LLC [Member]
Disclosure Of Significant Investments In Subsidiaries [Line Items]
Name of subsidiary	Benitec LLC (subsidiary of Benitec Inc)
Principal place of business	USA
Country of incorporation	USA
Ownership percentage in subsidiary	100.00%	100.00%	100.00%
RNAi Therapeutics, Inc. [Member]
Disclosure Of Significant Investments In Subsidiaries [Line Items]
Name of subsidiary	RNAi Therapeutics, Inc.
Principal place of business	USA
Country of incorporation	USA
Ownership percentage in subsidiary	100.00%	100.00%	100.00%
Tacere Therapeutics, Inc. [Member]
Disclosure Of Significant Investments In Subsidiaries [Line Items]
Name of subsidiary	Tacere Therapeutics, Inc.
Principal place of business	USA
Country of incorporation	USA
Ownership percentage in subsidiary	100.00%	100.00%	100.00%

Events After the Reporting Pe_2

Events After the Reporting Period - Additional Information (Detail) - Jul. 09, 2018 - Axovant Sciences [Member] - License Agreement and Fully Funded Collaboration [Member] $ in Millions	AUD ($)ProductMilestone	USD ($)ProductMilestone	USD ($)
Disclosure of non-adjusting events after reporting period [Line Items]
Number of additional products | Product	5	5
Upfront cash payment received	$ 13.5	$ 10,000,000
Additional cash payment	$ 23.6		$ 17,500,000
Number of milestones achievable	8	8
Number of near term milestones achievable	4	4
Maximum amount realizable upon completion of milestones	$ 253.3		$ 187,500,000
Percentage of net profit on sales	30.00%	30.00%

Reconciliation of Loss after _3

Reconciliation of Loss after Income Tax to Net Cash Used in Operating Activities - Summary of Reconciliation of Loss after income Tax to Net Cash Used in Operating Activities (Detail) - AUD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2016
Reconciliation Of Loss After Income Tax To Net Cash Used In Operating Activities [Abstract]
Loss after income tax benefit for the year	$ (11,640)	$ (5,690)	$ (24,778)
Adjustments for:
Loss on disposal of fixed assets	1	6
Depreciation and amortisation	194	217	290
Share-based payments	434	386	1,746
Net unrealised Foreign exchange	(82)	242	506
Issue of ordinary shares to Biomics			500
Impairment of prepayment			1,800
Change in operating assets and liabilities:
Increase in trade and other receivables	72	814	(854)
(Decrease) in other current assets	(121)	(182)	1,178
Increase in trade and other payables	1,259	114	(623)
(Decrease) in R&D grant receivable	112	(4,233)
(Decrease) in employee benefits	(23)	(3)	27
Increase in provision		25
Net cash used in operating activities	$ (9,794)	$ (8,304)	$ (20,208)

Earnings Per Share - Summary of

Earnings Per Share - Summary of Earnings Per Share (Detail) - AUD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2016
Earnings Per Share [Abstract]
Loss after income tax attributable to the owners of Benitec Biopharma Limited	$ (11,640)	$ (5,690)	$ (24,778)
Weighted average number of ordinary shares used in calculating basic earnings per share	210,454,829	175,433,909	142,312,486
Weighted average number of ordinary shares used in calculating diluted earnings per share	210,454,829	175,433,909	142,312,486
Basic (loss) per share	$ (0.0553)	$ (0.0324)	$ (0.1741)
Diluted (loss) per share	$ (0.0553)	$ (0.0324)	$ (0.1741)

Share-based Payments - Summary

Share-based Payments - Summary of Number and Weighted Average Exercise Price of Share Options (Detail)	12 Months Ended
	Jun. 30, 2018AUD ($)shares	Jun. 30, 2017AUD ($)shares	Jun. 30, 2016AUD ($)shares
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Abstract]
Number of shares, Outstanding at the beginning of the year	9,724,000	12,220,000	12,500,000
Number of shares, Granted during the year	19,950,000	2,200,000	6,720,000
Number of shares, Lapsed or forfeited during the year	(5,196,668)	(4,696,000)	(7,000,000)
Number of shares, Outstanding at the end of the year	24,477,332	9,724,000	12,220,000
Number of shares, Options exercisable at the end of the year	6,527,333	6,497,333	8,292,000
Weighted average exercise price, Outstanding at the beginning of the year | $	$ 0.832	$ 1.079	$ 1.234
Weighted average exercise price, Granted during the year | $	0.218	0.166	0.770
Weighted average exercise price, Lapsed or forfeited during the year | $	0.426	1.164	1.060
Weighted average exercise price, Outstanding at the end of the year | $	$ 0.416	$ 0.832	$ 1.079

Share-based Payments - Summar_2

Share-based Payments - Summary of Details of ESOP Share Options Outstanding (Details)	12 Months Ended
	Jun. 30, 2018AUD ($)shares	Jun. 30, 2017shares	Jun. 30, 2016shares	Jun. 30, 2015shares
Disclosure Of Range Of Exercise Prices Of Outstanding Share Options [Line Items]
Number of option | shares	24,477,332	9,724,000	12,220,000	12,500,000
September 26, 2011
Disclosure Of Range Of Exercise Prices Of Outstanding Share Options [Line Items]
Grant date	September 26, 2011
Expiry date	Sep. 26, 2016
Exercise price	$ 1.250
Number of option | shares			2,800,000
February 7, 2012
Disclosure Of Range Of Exercise Prices Of Outstanding Share Options [Line Items]
Grant date	February 7, 2012
Expiry date	Feb. 7, 2017
Exercise price	$ 1.250
Number of option | shares			156,000
November 6, 2012
Disclosure Of Range Of Exercise Prices Of Outstanding Share Options [Line Items]
Grant date	November 6, 2012
Expiry date	Nov. 6, 2017
Exercise price	$ 1.250
Number of option | shares			400,000
July 17, 2017
Disclosure Of Range Of Exercise Prices Of Outstanding Share Options [Line Items]
Grant date	July 17, 2017
Expiry date	Jul. 17, 2022
Exercise price	$ 0.196
April 11, 2018
Disclosure Of Range Of Exercise Prices Of Outstanding Share Options [Line Items]
Grant date	April 11, 2018
Expiry date	Apr. 11, 2023
Exercise price	$ 0.298
June 26, 2018
Disclosure Of Range Of Exercise Prices Of Outstanding Share Options [Line Items]
Grant date	June 26, 2018
Expiry date	Jun. 26, 2023
Exercise price	$ 0.228
Employee Stock Ownership Plan [Member] | November 17, 2012
Disclosure Of Range Of Exercise Prices Of Outstanding Share Options [Line Items]
Grant date	November 17, 2012
Expiry date	Nov. 17, 2017
Exercise price	$ 1.250
Number of option | shares		400,000	600,000
Employee Stock Ownership Plan [Member] | August 22, 2013
Disclosure Of Range Of Exercise Prices Of Outstanding Share Options [Line Items]
Grant date	August 22, 2013
Expiry date	Aug. 22, 2018
Exercise price	$ 1.250
Number of option | shares	480,000	480,000	480,000
Employee Stock Ownership Plan [Member] | May 15, 2014
Disclosure Of Range Of Exercise Prices Of Outstanding Share Options [Line Items]
Grant date	May 15, 2014
Expiry date	May 15, 2019
Exercise price	$ 1.500
Number of option | shares	90,000	180,000	180,000
Employee Stock Ownership Plan [Member] | December 17, 2014
Disclosure Of Range Of Exercise Prices Of Outstanding Share Options [Line Items]
Grant date	December 17, 2014
Expiry date	Dec. 17, 2019
Exercise price	$ 1.250
Number of option | shares	2,334,000	2,334,000	2,634,000
Employee Stock Ownership Plan [Member] | May 6, 2015
Disclosure Of Range Of Exercise Prices Of Outstanding Share Options [Line Items]
Grant date	May 6, 2015
Expiry date	May 6, 2020
Exercise price	$ 1.250
Number of option | shares	650,000	650,000	650,000
Employee Stock Ownership Plan [Member] | August 9, 2016
Disclosure Of Range Of Exercise Prices Of Outstanding Share Options [Line Items]
Grant date	August 9, 2016
Expiry date	Aug. 9, 2021
Exercise price	$ 0.167
Number of option | shares	1,466,666	2,200,000
Employee Stock Ownership Plan [Member] | July 17, 2017
Disclosure Of Range Of Exercise Prices Of Outstanding Share Options [Line Items]
Grant date	July 17, 2017
Expiry date	Jul. 17, 2022
Exercise price	$ 0.196
Number of option | shares	6,566,666
Employee Stock Ownership Plan [Member] | April 11, 2018
Disclosure Of Range Of Exercise Prices Of Outstanding Share Options [Line Items]
Grant date	April 11, 2018
Expiry date	Apr. 11, 2023
Exercise price	$ 0.298
Number of option | shares	650,000
Employee Stock Ownership Plan [Member] | June 26, 2018
Disclosure Of Range Of Exercise Prices Of Outstanding Share Options [Line Items]
Grant date	June 26, 2018
Expiry date	Jun. 26, 2023
Exercise price	$ 0.228
Number of option | shares	10,000,000
Non-Executive Directors Options [Member] | November 10, 2013
Disclosure Of Range Of Exercise Prices Of Outstanding Share Options [Line Items]
Grant date	November 10, 2013
Expiry date	May 18, 2018
Exercise price	$ 0.620
Number of option | shares		400,000	400,000
Non-Executive Directors Options [Member] | November 12, 2015
Disclosure Of Range Of Exercise Prices Of Outstanding Share Options [Line Items]
Grant date	November 12, 2015
Expiry date	Nov. 12, 2020
Exercise price	$ 0.770
Number of option | shares	2,240,000	3,080,000	3,920,000

Share-based Payments - Addition

Share-based Payments - Additional Information (Details) $ in Thousands	12 Months Ended
	Jun. 30, 2018AUD ($)yr	Jun. 30, 2017AUD ($)yr	Jun. 30, 2016AUD ($)yr
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Abstract]
Weighted average remaining life of options | yr	3.833	2.833	2.583
Expenses arising from share-based payment transactions recognized during the period | $	$ 434	$ 386	$ 1,746

Share-based Payments - Summar_3

Share-based Payments - Summary of Valuation Model Inputs used to Determine the Fair Value at the Grant Date (Details)	12 Months Ended
	Jun. 30, 2018AUD ($)$ / shares
17/07/2017
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Grant date	July 17, 2017
Expiry date	Jul. 17, 2022
Share price at grant date | $ / shares	$ 0.130
Exercise price	$ 0.196
Expected volatility	100.01%
Risk-free interest rate	2.37%
Fair value at grant date	$ 0.091
11/04/2018
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Grant date	April 11, 2018
Expiry date	Apr. 11, 2023
Share price at grant date | $ / shares	$ 0.200
Exercise price	$ 0.298
Expected volatility	101.43%
Risk-free interest rate	2.373%
Fair value at grant date	$ 0.141
26/06/2018
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Grant date	June 26, 2018
Expiry date	Jun. 26, 2023
Share price at grant date | $ / shares	$ 0.145
Exercise price	$ 0.228
Expected volatility	100.31%
Risk-free interest rate	2.303%
Fair value at grant date	$ 0.100